Procedural guidance for the systematic evaluation of biomarker tests by Kisser, A. & Zechmeister-Koss, I.
 Procedural guidance 
for the systematic 
evaluation of 
biomarker tests 
 
 
Version 1.2, November 2014 
 
 
Decision Support Document Nr. 77 
ISSN-online: 1 899 -0 64 9 

 Procedural guidance 
for the systematic 
evaluation of 
biomarker tests 
 
 
Version 1.2, November 2014 
 
 
Vienna, November 2014 
 Project team 
Project head: Dr. Ingrid Zechmeister-Koss 
Project team: Dr. Agnes Kisser 
 
Project support  
External review: Tracy Merlin, AHTA, Australia 
Stefan Lange, IQWIG, Germany 
Petra Schnell-Inderst, UMIT, Austria 
Internal review: PD Dr. Claudia Wild 
 
Correspondence: Dr. Agnes Kisser, agnes.kisser@hta.lbg.ac.at  
 
 
Dieser Bericht soll folgendermaßen zitiert werden/This report should be referenced as follows: 
Kisser A & Zechmeister-Koss I. Procedural guidance for the systematic evaluation of biomarker tests.  
Decision Support Document Nr. 77; 2014. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment. 
 
Conflicts of interest 
The authors declare no conflicts of interest according to the Uniform  
Requirements of Manuscripts Statement of Medical Journal Editors (www.icmje.org). 
 
IMPRESSUM 
Medieninhaber und Herausgeber: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Wien 
http://www.lbg.ac.at/de/themen/impressum 
Für den Inhalt verantwortlich: 
Ludwig Boltzmann Institut für Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Wien 
http://hta.lbg.ac.at/ 
Die HTA-Projektberichte erscheinen unregelmäßig und dienen der Veröffentlichung der Forschungsergebnisse 
des Ludwig Boltzmann Instituts für Health Technology Assessment. 
Die HTA-Projektberichte erscheinen in geringer Auflage im Druck und werden über den Dokumentenserver 
„http://eprints.hta.lbg.ac.at“ der Öffentlichkeit zur Verfügung gestellt: 
Decision Support Document Nr.: 77 
ISSN: 1992-0488 
ISSN-online: 1992-0496 
© 2014 LBI-HTA – Alle Rechte vorbehalten 
 LBI-HTA | 2014 3 
Contents 
1 Introduction .......................................................................................................................................................... 5 
2 Method ................................................................................................................................................................... 7 
3 Terminology and classifications ........................................................................................................................ 9 
3.1 Definition: Biomarker .................................................................................................................................. 9 
3.2 Differentiation of functions of biomarkers .............................................................................................. 10 
3.3 Medical tests ............................................................................................................................................... 11 
3.4 Evaluation framework ................................................................................................................................ 12 
4 Context for analysis ........................................................................................................................................... 15 
4.1 Developing an analytical framework ........................................................................................................ 15 
4.2 Formulation of review question with PICO ............................................................................................. 16 
4.2.1 Population ...................................................................................................................................... 16 
4.2.2 Intervention: new test- and treatment strategy ............................................................................ 16 
4.2.3 Comparator: existing test and treatment strategy ....................................................................... 17 
4.2.4 Outcomes ........................................................................................................................................ 18 
5 Identifying the evidence base ........................................................................................................................... 21 
5.1 Literature search and selection ................................................................................................................. 21 
5.2 Hierarchies of evidence/Study designs ..................................................................................................... 21 
5.2.1 Diagnostic accuracy ....................................................................................................................... 22 
5.2.2 Prognosis and Aetiology ................................................................................................................ 23 
5.2.3 Clinical trial designs ...................................................................................................................... 25 
6 Critical appraisal ................................................................................................................................................ 29 
6.1 Internal validity .......................................................................................................................................... 29 
6.1.1 Diagnostic accuracy studies .......................................................................................................... 29 
6.1.2 Prognosis studies ............................................................................................................................ 31 
6.2 Strength of the body of evidence ............................................................................................................... 34 
6.2.1 Adaptations of the GRADE framework to diagnostic accuracy and prognosis studies ............ 34 
6.2.2 Assessment of co-dependent technologies .................................................................................... 37 
7 References ............................................................................................................................................................ 41 
8 Annexes ................................................................................................................................................................ 47 
8.1 Formulation of review question: Checklist to assess context of submission and impact on 
clinical practice ........................................................................................................................................... 47 
8.2 Qualification: assessing the impact of a biomarker test on patient health outcomes ........................... 50 
 
  
Procedural guidance for the systematic evaluation of biomarker tests 
4 LBI-HTA | 2014 
Figures 
Figure 3.4-1: The three interdependent tiers of biomarker evaluation  ............................................................... 13 
Figure 4.1-1: Analytical framework for the evaluation of medical tests  .............................................................. 15 
Figure 4.2-1: Options for integration of a medical test in an existing testing strategy  
(+ and – indicate positive or negative test results).  ........................................................................ 17 
Figure 5.2-1: Randomised clinical trial designs for biomarker evaluation  ......................................................... 28 
 
 
Tables 
Table 2-1: Method guidelines and reports included ............................................................................................ 8 
Table 3.1-1: Analytical technologies in biomarker research: overview of research areas,  
biological entities and processes studied; present and future applications ..................................... 9 
Table 3.4-1: Steps in the evaluation of biomarkers ............................................................................................... 13 
Table 5.2-1: Evidence hierarchies by research questions ..................................................................................... 24 
Table 5.2-2: List of effects that can be assessed and questions that can be answered  
by the trials of each design category ................................................................................................. 27 
Table 6.1-1: QUADAS-2 Checklist for assessment of Risk of Bias in Diagnostic Accuracy Studies ................ 30 
Table 6.1-2: Classification of indeterminate results by “Intention to Diagnose” .............................................. 31 
Table 6.1-3: QUIPS tool for the assessment of bias in studies of prognostic factors ......................................... 32 
Table 6.2-1: QUADAS-2 checklist for the assessment of applicability  
in diagnostic accuracy studies ........................................................................................................... 35 
Table 6.2-2: Tabular presentation of the changes in classification induced by a new test compared to 
standard strategy – Example: p16/Ki-67 triage compared with direct referral to colposcopy ......... 36 
Table 6.2-3: Differentiation of biomarker types by impact on health outcomes ................................................ 38 
Table 8.1-1: Checklist – rationale for co-dependent relationship between test (T) and drug (D). 
(O) – overlap between test and drug. ................................................................................................ 47 
Table 8.2-1: Checklist: Clinical benefit of the pair of co‐dependent technologies  
in terms of patient health outcomes .................................................................................................. 50 
 
 
 LBI-HTA | 2014 5 
1 Introduction 
Personalised Medicine seeks to improve stratification and timing of health 
care by utilising biological information and biomarkers on the level of mo-
lecular disease pathways, genetics, proteomics as well as metabolomics [1]. 
These biomarker tests only deploy their value through influencing subsequent 
clinical decisions and in conjunction with subsequent treatments. The in-
creasing numbers of biomarker tests in clinical routine require an adapta-
tion of current assessment of diagnostics and medical tests to precisely de-
termine the value of each test in a given setting. 
With the sequencing of the human genome in 2001 and the fast development 
of the –omics technologies, expectations are high, that biological processes 
including disease progression and treatment reactions can be measured ac-
curately and even predicted on a molecular level. Association studies yield 
vast numbers of potential biomarker candidates, but so far there is no defini-
tive consensus on the evidentiary requirements for the evaluation of bio-
marker tests for clinical routine. Diagnostic accuracy represents an important 
but not by itself sufficient characteristic of biomarker tests. Common chal-
lenges in the evaluation of biomarkers and medical tests are the assessment 
of multiple steps in a clinical path (test and treatment), methodological chal-
lenges in systematic reviews of diagnostic accuracy and prognostic tests, the 
lack of direct evidence from (double) randomised clinical trials and the com-
plex assessment of the applicability of the test and treatment strategy. 
It was our aim to analyse the approaches proposed in methodological guide-
lines by leading HTA institutes and to extract a procedural guidance for the 
evaluation of research questions beyond the classical therapeutic interven-
tion, triggered by the increasing importance of biomarkers and medical tests 
in medical routine. The document is meant to complement the LBI internal 
manual for qualitative evidence synthesis on effectiveness and safety of med-
ical technologies [2]. Only steps in the assessment which deviate or need spe-
cial attention are covered, and methods of quantitative evidence synthesis and 
cost-effectiveness are excluded. This report is a living document and is meant 
to be subject for development over time. 
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2 Method 
The report is not intended to provide a systematic review of the topic. Find-
ings are based on a limited literature search that was conducted using the 
Pubmed and Medline bibliographic databases and inclusion of references was 
restricted to English and German language documents. Grey literature was 
identified by searching a variety of websites from HTA institutes or EBM re-
search institutes for reports and guidelines addressing the specific challenges 
in the assessment of diagnostics, biomarkers and medical tests and providing 
methodological guidance. Further references were gathered by a snowball 
system in the references of the reports identified and conference abstracts 
from the 2013 Symposium “Methods for Evaluating Medical Tests and Bio-
markers” at the University of Birmingham or were suggested by the reviewers. 
We compared the terminology used in the methodology papers and mapped 
them to the steps in the evaluation process. We identified areas with missing 
methodological consensus and compared the solutions proposed. The meth-
od guidelines and reports included in this report are summarised in Table 
2-1. In line with the scope of the report, we did not include publications cov-
ering meta-analysis, decision modelling or cost-effectiveness analysis. 
The structure of the report corresponds to the sequence of steps involved in 
the assessment of a medical test from formulating the research question to the 
synthesis of the evidence as described in the LBI-HTA’s internal manual [2]. 
In a first section, we provide definitions and clarifications of the often vary-
ing terminology used in the field. This is followed by guidance for the devel-
opment of the analytical framework and the formulation of the PICO ques-
tion. New study designs likely to be encountered in reviews of biomarker tests 
are presented together with alternative evidence hierarchies. Finally guid-
ance is provided on how to assess bias and applicability in alternative study 
designs and how to grade the available evidence. The report is not a com-
prehensive catalogue of methods, but aims to emphasise the issues specific 
to the evaluation of biomarkers and medical tests and provide references to 
detailed method guidelines, where necessary. 
 
unsystematic review: 
literature search in 
Pubmed, Medline and 
hand search for grey 
literature 
structure of the report 
corresponds to steps  
in assessment 
 
highlight specific issues 
Procedural guidance for the systematic evaluation of biomarker tests 
8 LBI-HTA | 2014 
Table 2-1: Method guidelines and reports included 
Institution Title Reference 
Agency for Healthcare 
Research and Quality's 
(AHRQ) 
Methods Guide for 
Medical Test Reviews 
AHRQ Publication No. 12-EC017. Rockville, MD:  
Agency for Healthcare Research and Quality; June 2012. 
Available from: 
www.effectivehealthcare.ahrq.gov/reports/final.cfm 
Also published as a special supplement to the Journal of 
General Internal Medicine, July 2012. 
The Cochrane 
Collaboration 
Cochrane Handbook for 
Systematic Reviews of 
Diagnostic Test Accuracy 
Version 0.9 
Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane 
Handbook for Systematic Reviews of Diagnostic Test 
Accuracy Version 0.9.0.The Cochrane Collaboration, 2010 
Available from: http://srdta.cochrane.org/ 
National Health Care 
Institute (Zorginstituut 
Nederland, formerly 
CVZ) 
Medical tests (assessment 
of established medical 
science and medical 
practice) 
Derksen J. 2011; CVZ Report 293. Available from 
http://www.zorginstituutnederland.nl/publicaties 
GRADE Working 
Group.  
Grading quality of 
evidence and strength of 
recommendations in 
clinical practice guidelines: 
Part 2 of 3. The GRADE 
approach to grading 
quality of evidence about 
diagnostic tests and 
strategies 
Brozek JL, Akl EA, Jaeschke R, Lang DM, Bossuyt P, Glasziou 
P, Helfand M, Ueffing E, Alonso-Coello P, Meerpohl J, Phillips 
B, Horvath AR, Bousquet J, Guyatt GH, Schünemann HJ; 
GRADE Working Group. Allergy. 2009 Aug;64(8):1109-16 
Available from http://dx.doi.org/10.1111/j.1398-
9995.2009.02083.x 
Institut für Qualität 
und Wirtschaftlichkeit 
im Gesundheitswesen 
(IQWIG)  
Allgemeine Methoden 
Version 4.1. 2013 
Available from http://www.iqwig.de 
Medical Services 
Advisory Committee 
(MSAC) 
Guidelines for the 
Assessment of Diagnostic 
Technologies 
Canberra, Australia, Commonwealth of Australia, 2005. 
Available from http://www.msac.gov.au/ 
Adelaide Health 
Technology Assessment 
(AHTA) 
Assessing Personalized 
Medicines in Australia:  
A National Framework for 
Reviewing Codependent 
Technologies 
Tracy Merlin, Claude Farah, Camille Schubert, Andrew 
Mitchell, Janet E. Hiller and Philip Ryan. Med Decis Making. 
Apr 2013; 33(3): 333–342. 
Available from http://dx.doi.org/10.1177/0272989X12452341 
National Institute of 
Health and Clinical 
Excellence (NICE) 
Diagnostics Assessment 
Programme manual 
December 2011. 
Available from http://www.nice.org.uk/ 
Institute of Medicine 
(IOM) 
Evaluation of biomarkers 
and surrogate endpoints 
in chronic disease 
Washington; DC: The National Academies Press, 2010. 
Available from 
http://www.iom.edu/Reports/2010/Evaluation-of-Biomarkers-
and-Surrogate-Endpoints-in-Chronic-Disease.aspx  
Ludwig Boltzmann 
Institute for Health 
Technology Assessment 
(LBI-HTA) 
Evaluation von 
Diagnostika – Hintergrund, 
Probleme, Methoden 
Nachtnebel A. HTA Projektbericht Nr 36. 2010. 
Available from http://eprints.hta.lbg.ac.at/898/ 
Centre for Reviews and 
Dissemination, 
University of York 
(CRD) 
Chapter 2 Systematic 
reviews of clinical tests in: 
Systematic Reviews.  
The CRD’s guidance for 
undertaking reviews in 
health care., 2009 
Centre for Reviews and Dissemination, University of York, 
2009. P.109ff 
Available from 
http://www.york.ac.uk/inst/crd/pdf/Systematic_Reviews.pdf 
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3 Terminology and classifications 
3.1 Definition: Biomarker 
According to the definition of the National Institute for Health (NIH) a bio-
marker is „a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmaco-
logical responses to a therapeutic intervention“ [13]. This broad definition 
allows for a large variety of biomarkers, from the analysis of small molecules 
up to the examination of physical parameters such as blood pressure. Table 
3.1-1 presents an overview of the analytical technologies used in biomarker 
research and the biological processes, entities and examples of applications 
associated with each technology.  
Table 3.1-1: Analytical technologies in biomarker research:  
overview of research areas, biological entities and processes studied; present and future applications  
Research area Biological entity Biological Process Examples of applications 
Genomics Gene characteristics 
(Variations in 
sequence, copy 
number, epigenetic 
modification) 
Gene expression 
Gene function 
Gene regulation 
Pharmacogenomics/-genetics:  
response to medication 
Nutrigenomics:  
effects of food and food constituents 
Epigenomics:  effects of epigenetic modifications 
Metagenomics: study of communities of 
microbial organism (e.g. gut flora) 
Immunomics: study of immune system 
regulation and responses to pathogens 
Transcriptomics mRNA characteristics 
(Variations in sequence, 
expression levels, 
processing, splicing, 
editing) 
Gene expression Metatranscriptomics: study of communities of 
microbial organism (e.g. gut flora) 
Proteomics Proteins (Structure, 
posttranslational 
modifications) 
Protein expression 
Protein-protein-
interactions 
Protein function 
and activity 
Protein secretion 
Immunoproteomics: study of proteomes in 
immune response 
Secretomics: analysis of the secreted proteins in 
a cell 
Metabolomics Metabolites  
(small molecules) 
Metabolic profile 
Biochemical 
pathways  
Toxicology: metabolic profiling of the response 
to toxic insult of a chemical or drug 
Nutrigenomics (see above) 
Lipidomics: analysis of lipid species within a cell 
or tissue 
Imaging Cell 
Tissue 
Organ 
Growth rate, 
metabolic rate, 
Plaque formation 
Inflammation 
Pharmacokinetics: analysis of time course of 
drug absorption, distribution, metabolism, and 
excretion. 
Pharmacodynamics: biochemical and physical 
effects of a drug on the body 
Physical or 
physiological 
measurements 
Whole body various Biomarkers of ageing  
(e.g. muscle mass, muscle strength) 
Multiple sclerosis biomarkers  
(e.g. walking capacity) 
(Source: own presentation) 
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These technological categories however do neither align with functional dif-
ferentiation of biomarkers nor with specific diseases (despite certain associa-
tions such as e.g. cancer – genomics or diabetes – metabolomics). The appli-
cations widely vary with regards to their stage of development: while a num-
ber of genomic, imaging and whole body biomarkers are already in use in clin-
ical practice, many others areas are still in the stage of early basic research 
and hypothesis generation in association studies.  
 
 
3.2 Differentiation of functions of biomarkers  
The methodology of HTA evaluation of a biomarker test is independent of 
the technological category of the biomarker with one exception: genetic/ge-
nomic biomarkers require a particular consideration as health and non-health 
related (e.g. ethical, social and legal) effects may affect more than one gener-
ation. To identify the outcomes relevant for the evaluation in a specific con-
text of use, it is useful to differentiate biomarkers by the type of information 
they provide and the context of their use in clinical practice, detailed below 
[13-15]. As a principle, any biomarker is only useful if the test results are as-
sociated with appropriate differential treatment options. 
Differentiation by type of information 
 Diagnostic biomarkers are used to identify patients with a particular 
health condition, and to differentiate it from other conditions with 
similar symptoms, requiring differential treatment. Tests for diagnos-
tic biomarkers may be used as replacement for time-consuming, ex-
pensive or invasive diagnostic procedures (e.g. replacement of echo-
cardiogramm by testing levels of brain natriuretic peptides to rule out 
heart disease), or as an Add-on to existing methods to further refine 
the diagnosis. Diagnostic biomarkers can be used as screening markers 
to identify persons with an underlying disease in a screening popula-
tion. (Example: elevated blood glucose concentration for the diagno-
sis of diabetes mellitus). 
 Prognostic biomarkers predict the likely course of a disease in patients 
regardless of the treatment given. They can be used for risk stratifica-
tion (triage) of patients based on their risk of disease progression to 
avoid expensive or invasive treatments and to ensure an optimal dis-
tribution of resources. Prognostic biomarkers may also be used in a 
screening population to identify people at risk to develop a specific 
health condition: these so-called risk biomarkers are indicative of a 
changed physiological state that is associated with a risk of disease. 
Several prognostic markers can be combined in a prediction model. 
(Example: fibrinogen for prognosis of primary stroke [16]). 
 Predictive biomarkers (theranostic biomarker) predict the response of 
the patients to a specific treatment in comparison to the standard treat-
ment, placebo or observation only (the biomarker (information) x treat-
ment (effect) interaction). They are used for treatment stratification 
and guide choice of treatment [17]. (In vitro) Companion diagnostics 
are defined as “in vitro diagnostics that provide information that is essential 
for the safe and effective use of a corresponding therapeutic” (FDA Defini-
tion, [18]): here the use of a specific treatment is obligatorily preced-
ed by a test for this predictive biomarker (Example: Trastuzumab/ 
HER2 testing for breast cancer).  
differentiation by  
type of information 
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Differentiation by the context of use 
 Screening markers are used to detect disease in asymptomatic or pre-
symptomatic persons and are used for prevention. They may provide 
diagnostic or prognostic information. 
 Aetiologic markers are similar to prognostic markers in that both are 
risk factors for a specific outcome, but should be differentiated by the 
population they relate to: in prognosis all the population has the same 
disease/condition, in aetiology the marker serves to differentiate be-
tween individuals with/without the condition and to identify causal 
risk factors for a specific condition. 
 Monitoring biomarkers are used for surveillance of the response to 
treatment (Example CEA and PSA for monitoring of tumor status 
during therapy and between image evaluations [19]). 
 Surrogate endpoints are laboratory measurements or physical signs 
used in therapeutic trials as a substitute for a clinically meaningful 
endpoint. “A surrogate endpoint is expected to predict clinical benefit 
(or harm or lack of benefit or harm) based on epidemiologic, thera-
peutic, pathophysiologic, or other scientific evidence”[13]. 
 
 For a more in-depth overview and discussion of definitions refer to:  
Surrogate biomarkers: [11], Chapter 1, p.17ff 
 Diagnostic/Prognostic/Predictive biomarkers: [13, 14] 
 
 
3.3 Medical tests 
By definition a biomarker must not only represent a specific biological pro-
cess, but it must also be objectively measurable. Thus, biomarkers are always 
associated with a corresponding medical test. The test must be applicable in 
clinical routine, reproducible and accurately translate the biomarker into a 
measurement parameter. Often several tests are available to measure the same 
biomarker – in this case evaluation not only takes into account the specific 
test performance characteristics but also costs and handling of the test might 
become decisive factors.  
Medical tests can be differentiated by test methodology: 
1. Imaging  
This category comprises Radiology (classic X-Ray), Sonography (Ul-
trasound), X ray, Computed tomography, magnetic resonance imag-
ing, angiography, positron emission tomography, and other methods 
of nuclear medicine.  
2. Analysis of body fluids or smears  
Most frequently analysed body fluids are blood, urine and cerebrospi-
nal fluid; less common are synovial fluid, sweat, saliva and gastric juic-
es. The analysis involves chemical or molecular biologic assays and 
cytologic examinations of cell smears or suspensions. 
3. Endoscopy  
This consists in the investigation of interiors of organs or body cavities 
with an endoscope (viewing tube), that is introduced through a small 
incision or an existing body orifice (nose, mouth, anus, urethra, vagina).  
differentiation  
by context of use 
biomarkers must be 
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types of tests can be 
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4. Measurement of body functions  
Examples for this category are the measurement of blood pressure, 
the measurement of the electrical activity of the heart (Electrocardi-
ography, ECG) or of the brain (Electroencephalography, EEG). 
5. Examination of biopsies 
This consists in the removal of a tissue sample followed by the histo-
logical examination of the tissue. The analysis of the biopsy may also 
involve chemical or molecular biologic tests. 
 
 
3.4 Evaluation framework 
The purpose of a systematic review of any medical test is to identify and pre-
sent evidence of its clinical utility: the health outcomes associated with its 
use [3, 5, 10, 14, 20]. Unlike the outcomes of therapeutic interventions, the 
clinical outcomes of medical tests are only in part directly induced by the test 
procedure but most of them indirectly by patient management decisions and 
treatments initiated according to the test results. The majority of the studies 
evaluating medical tests cover only segments of this path. 
A number of frameworks have already been proposed for the evaluation of 
medical tests [20, 21]. Organising frameworks can and should be “used to 
categorise key questions and suggest which types of studies would be most 
useful for the review” [3, p.2-6]. These parameters can be mapped to the three-
step evaluation process (Figure 3.4-1) proposed by IOM, USA, in 2010 [11]. 
The IOM framework shows the interdependency of the various steps, i.e. a 
change in technical parameters will require a re-evaluation of patient-relevant 
outcomes, and it specifically includes the contextual analysis and the assess-
ment with regards to the specific context of use. Especially for diagnostics 
clinical practice of testing algorithms may strongly vary between countries. 
This process comprises three interrelated tiers, that can be assessed individ-
ually but need to be correlated to come to a final evaluation: 
 Analytical validation describes the ability of a test to reliably and ac-
curately measure a biomarker of interest, including limits of detection, 
limits of quantitation, reference value cut-off concentration, reliabil-
ity and reproducibility.  
 The qualification step comprises the actual evidentiary assessment of 
the association between biomarker and disease states. In the case of 
surrogate biomarkers the qualification step includes in addition as-
sessment of evidence that interventions targeting the biomarker have 
an impact on health outcomes. Evidence on the impact on health out-
comes can be provided by direct or by indirect evidence. 
 The third step of biomarker evaluation – utilisation – consists in the 
analysis of the evidence “with regard to the proposed use of the bio-
marker”. In this step, evaluators should take into consideration the 
specific context of use of the biomarker with regards to target popula-
tion, setting and purpose of the biomarker.  
clinical outcomes of 
medical tests are 
induced indirectly 
evaluation framework to 
identify and categorise 
key review questions 
analytical validation 
qualification 
utilisation 
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Figure 3.4-1: The three interdependent tiers of biomarker evaluation 
Source: [11] 
Table 3.4-1 gives an overview of the characteristics evaluated in each step of 
the biomarker evaluation, with example parameters. Where varying terms 
were used in the literature, they are listed in brackets below each of the evalu-
ation steps. 
Table 3.4-1: Steps in the evaluation of biomarkers  
Steps in Biomarker evaluation Biomarker characteristics evaluated Parameters (Examples) 
Analytical validation  
(Technical efficacy, analytical validity) 
Ability of a test/chemical assay to 
quantitate a biomarker of interest 
Technical quality of a radiological 
image, reproducibility, repeatability 
Qualification 1  
(Test accuracy –diagnostic/prognostic 
accuracy, clinical validity) 
Ability of a test to classify a patient 
into a disease, phenotype or 
prognosis category 
Sensitivity, specificity, SROC curve 
Qualification 2 
(Clinical utility, therapeutic efficacy, 
patient outcome efficacy) 
Ability of a test to improve patient 
outcomes 
Changes in patient management, 
mortality, morbidity. 
Utilization  
(Societal aspects, economic aspects) 
Contextual analysis and risk-benefit 
assessment with regard to the 
proposed use 
Opportunity costs 
SROC – Summary Receiver Operating Characteristic 
 
 For a more in-depth overview refer to:  
Three steps in the biomarker evaluation process: [11] p.5ff 
 Review of different types of analytical frameworks: [21] 
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4 Context for analysis 
4.1 Developing an analytical framework 
A systematic review is the method of choice for the evaluation of medical tests. 
The same quality criteria as for systematic reviews of therapeutic interven-
tions apply [2, 3, 12]. A specific challenge in the evaluation of medical tests 
is that more time needs to be dedicated to a careful definition of the review 
question to avoid ambiguity during literature search and literature selection 
and the evaluation of the selected studies. 
Due to the indirect influence on patient outcomes, a systematic review of a 
medical test starts with clarifying the embedment of the test in clinical rou-
tine and the implications resulting thereof. A useful tool is to create an ana-
lytical framework (Figure 4.1-1 for a schematic representation), including de-
cision making, further tests and treatments, patient outcomes and their sur-
rogates [22]. This might include liaising with relevant experts and also by tak-
ing into account the indications of the manufacturer. Often there are several 
scenarios possible with varying positions of the test in the diagnostic chain 
and in a first step the scenario(s) relevant to the commissioner of the study 
need(s) to be clarified. 
 
Figure 4.1-1: Analytical framework for the evaluation of medical tests  
Source: (Adapted from [8] and [22]) 
The evaluation of a medical test in a defined scenario has to take into account 
the specific context in which the test will be applied, as the context might in-
fluence test performance and vice-versa [3]. A widely accepted tool for the de-
scription of the context is the formulation of a PICO question, where P stands 
for Population, I for Intervention, C for Control intervention and O for Out-
comes [2].  
more time needed to 
develop review question 
clarify embedment of 
test in clinical routine 
and implications 
take into account 
specific context 
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4.2 Formulation of review question with PICO 
4.2.1 Population 
The review should clarify the target population of the test, i.e. to which pa-
tients the test is planned to be applied to. This includes information on  
 demographic characteristics (age, sex, ...),  
 medical history (prior diseases and treatments, co-morbidity, ...) 
 the clinical setting in which the test will be used (inpatient,  
ambulant/outpatient, doctor’s office, self-administration etc.) and 
 the prevalence of the target disease in the target population. 
 For prognostic markers: the observed probability (i.e. the observed 
proportion of an event in a given time period, [23, 24]) of the outcome 
being predicted. 
From the prevalence of the disease, the reviewer may deduce the pre-test 
probability of the target health condition in the population. In combination 
with the diagnostic accuracy parameters, the pre-test probability allows to cal-
culate the post-test probabilities.  
The detailed description of the target population is further required for the 
assessment of the available studies with regards to the applicability of their 
results to the review question.  
 
4.2.2 Intervention: new test- and treatment strategy 
An essential characteristic of medical tests is that they are generally not stand-
alone interventions, but embedded in a testing and treatment strategy, often 
with several sequential or parallel diagnostic tests and various treatment op-
tions according to specific combinations of test results, which will be influ-
enced by the embedding of the new test. By formulating the review question 
therefore the entire sequence of tests including the new test and treatments 
should be considered as the intervention under review.  
Bossuyt et al. identified three options how to integrate a medical test in an ex-
isting testing and treatment strategy depicted in Figure 4.2-1: Replacement, 
Triage or Add-on [25]. The purpose of a replacement test is usually to main-
tain the same test performance (sensitivity and specificity) as the existing test, 
while increasing cost-effectiveness or reducing adverse events due to inva-
sive procedures. Triage tests serve to avoid invasive or expensive procedures 
by decreasing unnecessary referrals. They should maintain the same sensitiv-
ity, since test-negatives of the new test will not be tested by the existing test, 
but may have lower specificity. Add-on tests finally serve to refine a diagno-
sis with the goal to improve treatment decisions and, thus, outcomes [26].  
Initial tests and patient management and treatment decisions need to be clari-
fied with relevant experts and guidelines to adjust to the national context.  
Description of the intervention should further include variants of the test, a 
definition of the cut-off point(s) and the timing of the application of the test 
(follow-up). Moreover the description of the test should include an assess-
ment of infrastructure and processes necessary for implementation of the test 
in practice.  
specify target 
population 
identify proposed test 
and treatment strategy 
options to integrate a 
test in an existing 
strategy 
clarify preceding tests 
and patient management 
decisions with experts 
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Figure 4.2-1: Options for integration of a medical test in an existing testing strategy  
(+ and – indicate positive or negative test results). 
Source: [25] 
In the assessment of biomarkers, the “intervention”, however, does not nec-
essarily include subsequent treatments: prognostic or etiologic marker may 
have as primary purpose to identify risk factors for a specific outcome.  
In diagnostic accuracy studies, the test, whose performance is evaluated is 
called “index test”. 
 
4.2.3 Comparator:  
existing test and treatment strategy 
As a principle, the comparator in reviews of medical tests is the current test 
and treatment strategy, i.e. the sequence of tests, patient management deci-
sions and treatments.  
In diagnostic accuracy studies, the comparison of a new and an existing test 
may be direct: in fully paired direct comparisons, where all participants re-
ceive the index test and one or more comparator tests. As an alternative par-
ticipants may be randomly allocated to receive the index or the comparator 
test (randomized direct comparison). The comparison is indirect, if the esti-
mates of diagnostic accuracy from different study populations are compared 
[27].  
The reference standard is used to define the target condition [28], i.e. to pro-
vide a classification of the disease for diagnosis or treatment decisions based 
on the best available evidence and to identify clinically relevant subgroups. 
The reference standard is the best available method to detect the target con-
dition. Downstream management decisions and the impact of treatments may 
vary in dependence of the chosen target condition and thus, the choice of the 
most appropriate reference standard for the review question should be clari-
fied by involving clinical guidelines and possibly experts. [28].  
comparator for the 
review: existing 
sequence of tests and 
treatment decisions 
 
 
diagnostic accuracy 
studies: direct or 
indirect comparison 
with other tests 
reference standard:  
used to define target 
condition in diagnostic 
accuracy studies 
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It is not possible to use the same test as reference standard and comparator 
test in a diagnostic accuracy study: diagnostic accuracy calculations are 
based on the assumption that the reference standard is “perfect”, i.e. capable 
of identifying “true” cases of disease and non-disease with 100% accuracy. 
This is problematic in circumstances where, in fact, the reference standard is 
poor and in cases where no reference standard is available. In these cases na-
ïve estimates1 of diagnostic accuracy are likely to be biased and are unsuita-
ble to substitute valid measurements of clinical outcomes [29]. In the ab-
sence of a perfect reference standard, the best way to determine diagnostic 
effectiveness would be a trial. A trial would also be required, if the index test 
is expected to have superior diagnostic accuracy to the current reference 
standard.  
 
4.2.4 Outcomes 
Accurate diagnosis is a prerequisite for a successful therapy, but it should not 
be seen in isolation. Instead, the benefit to patients resulting from diagnosis 
should be measured in patient-relevant outcomes [30], such as survival (mor-
tality), clinical events, adverse events, patient-reported outcomes (health re-
lated quality of life), activity and function. 
Based on the analytical framework developed, the reviewer should first ex-
plore all outcomes resulting from embedment of the test in the testing and 
treatment strategy in comparison to clinical practice without the test (as de-
scribed in ‘Intervention’ and ‘Comparator’). Reviewers should then make a 
careful selection of the relevant outcomes both to the process of testing and 
to the results of the test [31] by mapping them according to the following 
categories [31, 32]2: 
1. Clinical management effects due to testing  
2. Direct health effects of testing 
3. Emotional, social, cognitive, behavioural responses to testing 
4. Legal and ethical effects of testing 
A decision which outcomes are relevant for a review depends on the type of 
test under review and on the needs of the stakeholders of the study [31]. A 
review assessing the inclusion of a test in the benefits catalogue of health in-
surances or hospital interventions might be more restricted on outcomes di-
rectly affecting the patient, while a review serving medical guideline devel-
opment or the choice of a screening algorithm needs to take into account the 
outcomes on a societal level. As a consequence the prioritization of the rele-
vant outcomes should involve the commissioner of the study. The outcomes 
are decisive only if they differ between current and new testing and treatment 
strategy.  
The outcomes should explicitly be rated by importance a priori [30]. 
                                                             
1 Naïve estimates of diagnostic accuracy: parameters like sensitivity, specificity or 
positive and negative predictive value are calculated using 2x2 tables in which the 
positive and negative results of the reference standard are assumed to be the true 
numbers of sick and healthy, respectively. 
2 Only outcomes within the scope of this guidance were included (notably, costs were 
excluded). 
same test cannot be 
used as reference 
standard and 
comparator test in 
diagnostic accuracy 
studies 
selection and 
categorisation of 
relevant outcomes for 
the review 
dependent of type of 
test and purpose of  
the review 
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Clinical management effects due to testing 
This category describes the clinical consequences (in patient relevant out-
comes: mortality, morbidity and quality of life) that the use of a test will in-
duce. This includes expected consequences based on a negative (true negative, 
TN and false negative, FN) or positive (true positive, TP and false positive, 
FP) test result, as supported by primary literature on therapy decisions and 
outcomes in the particular setting under review. Further consequences might 
be induced by unexpected findings: they are particularly prominent in imag-
ing methods.  
Clinical management effects might be of particular importance in the evalu-
ation of diagnostic and prognostic tests [31].  
The desired management effects define which test performance parameters 
are of greatest importance: a test used to rule out the presence of a disease or 
a high risk for a disease should have high sensitivity and negative predictive 
value, NPV; a test used as “Add-on” to refine diagnosis should have high 
specificity or positive predictive value, PPV.  
 
Direct health effects of testing 
This category relates to the health effects that are directly induced by the 
test procedure and might be particularly relevant for invasive procedures or 
procedures that involve radiation, while other forms of testing (e.g. a vaginal 
swab) most likely will not have any health consequences. 
 
Emotional, social, cognitive, behavioral responses to testing 
Emotional responses might include relief or anxiety as a consequence of a test 
result – outcomes of this type might be particularly relevant in screening or 
prognostic tests. Test results might induce a change in behaviour in the tes-
tees – for example opting for a healthier lifestyle to compensate a high-risk 
prognosis or sustaining an unhealthy lifestyle as a consequence of a low-risk 
prognosis. Emotional responses might also be related to the test procedure 
itself – for example psychological symptoms following colonoscopy [33]. The 
effects might also extend to family members. Social issues such as stigmatiza-
tion, discrimination and privacy/confidentiality should also be considered. 
Genetic tests might have complex impact on behaviour, e.g. regarding family 
planning. 
 
Legal and ethical effects 
Legal consequences might arise in the case of reportable diseases (to be re-
ported by the health care provider) or diseases representing a safety threat in 
certain professions (pilots, surgeons, gastronomy ...), which warrant disclo-
sure to the employer. Besides disclosure or reporting requirements, legal is-
sues might involve consent, ownership of data and/or samples, patents, licens-
ing, proprietary testing.  
Genetic tests have a special status with regards to the ethical and legal effects 
because of the possible impact on family members. This depends on whether 
the testing is for inherited or acquired genetic mutations and the inheritance 
pattern of the trait. 
 
expected consequences 
in TN, FN, TP, FP groups 
relevant for  
invasive procedures 
e.g. change of behaviour 
e.g. test of  
reportable diseases 
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Based on the inventory of outcomes the reviewer will need to choose the rel-
evant outcomes for the review, depending on time and resources available and 
the intended purpose of the review. 
 
 A checklist for assessing the context of submission and the proposed 
impact of a biomarker test/technology on current clinical practice is 
proposed in [9](see also Annex).  
 The ACCE model proposes a checklist of targeted questions  
specifically for genetic testing [34]. 
 
 
select relevant 
outcomes 
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5 Identifying the evidence base 
To identify the evidence base relevant to a particular research question, a sys-
tematic literature search is conducted to identify all studies relevant to the 
research question and the evidence base is established based on the quantity 
and quality of the studies included [35]. 
 
 
5.1 Literature search and selection 
Several common challenges are associated with literature search for medical 
tests with the following key points [36]: 
1. Due to still underdeveloped indexing and reporting of studies of di-
agnostic tests, literature search should not rely (exclusively) on diag-
nostic search filters, in particular these filters are inappropriate for 
systematic review of clinical effectiveness. 
2. If the name(s) of the diagnostic test(s) relevant for the research ques-
tion is not known, search strategies should capture the “concept of 
diagnostic tests”3. 
3. To identify all studies for a systematic review, searches should include 
text words (not subject headings alone) and be combined with hand 
search including additional sources of information: specialised data-
bases, citation tracking and regulatory documents ([37]). 
 
 A thorough description of “Effective search strategies for systematic 
reviews of medical tests” is given by Relevo et al. in the AHRQ Methods 
Guide for Medical Test Reviews [36], p.4-1ff 
 
 
5.2 Hierarchies of evidence/Study designs 
For classical intervention research questions (therapeutic effectiveness), a hi-
erarchy of evidence has been established and is widely accepted based on the 
degree of bias associated with observational and non-randomised studies in 
comparison to randomised controlled trials [38-41]: this hierarchy attributes 
the highest level of evidence (Level I) to systematic reviews and meta-analyses 
of RCT and Level II to evidence obtained from at least one (properly de-
signed) RCT. Level III and IV subsequently refer to non-randomised compar-
ative studies and case series, respectively. Similarly, according to GRADE 
(Grading of Recommendations Assessment, Development and Evaluation), 
only RCTs are a priori considered to provide high quality evidence about treat-
ment effects [42]. 
                                                             
3 E.g. diagnosis OR diagnose OR diagnostic OR di[sh] OR “gold standard” OR “ROC” 
OR “receiver operating characteristic” OR sensitivity and specificity[mh] OR like-
lihood OR “false positive” OR “false negative” OR “true positive” OR “true negative” 
OR “predictive value” OR accuracy OR precision. 
systematic literature 
search 
studies on diagnostic 
tests poorly indexed: 
other search strategies 
need to be applied 
classical intervention: 
established evidence 
hierarchy 
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Study designs of biomarker studies may vary from classical intervention stud-
ies. This chapter is therefore meant to help reviewers to categorise the studies 
identified during literature search. 
As described in Chapter 3.4 – Evaluation framework, in order to fulfil the 
qualification step, evaluators first perform an evidentiary assessment on the 
causal relationship between biomarker and disease pathogenesis and second 
an assessment of the evidence that interventions targeting the (surrogate) bio-
marker impact the health outcome of interest [11].  
In principle, the most appropriate study design to evaluate the impact of a bio-
marker test on clinical management effects and health outcomes is a random-
ised controlled trial (RCT) [43, 44]. However the assessment of biomarkers 
does not necessarily include a classical intervention research question (ther-
apeutic effectiveness), but instead may include questions on prognosis, aeti-
ology, or diagnostic accuracy, depending on the context of use. For some of 
these questions the only evidence feasible and/or ethical will be from obser-
vational studies and different evidence hierarchies may apply [11, 43, 44]. To 
reflect this, revised evidence hierarchies have been elaborated by the NHMRC 
[43] and the Oxford Centre for Evidence-Based Medicine [44], which should 
be considered when prioritising available evidence. Table 5.2-1 presents an 
amalgamation of both evidence hierarchies. In all instances the highest level 
of evidence is provided by a systematic review of level II studies. 
 
5.2.1 Diagnostic accuracy 
Diagnostic accuracy studies are cross-sectional by nature. Study designs are 
differentiated in „Single-gate“ (diagnostic cohort study4) and „Two-gates“ (di-
agnostic case-control studies4) studies.  
In „Single-gate“ studies all study participants are first tested with an index 
test and then with the reference standard. Provided, all participants undergo 
both tests, the sequence of testing may be reversed (Reversed Flow Design), 
without influencing estimates of diagnostic accuracy [45]. “Two-gates” studies 
make comparisons between participants with confirmed disease/condition and 
healthy participants. The “Two-gate” design is intrinsically prone to spectrum 
bias, potentially leading to inflated estimates of the diagnostic accuracy [45, 
46]. Quality assessment should identify if a “Two-gate” study represents only 
a limited spectrum of disease and non-disease and if so, omit the study from 
the meta-analysis (if done) [47]. 
Diagnostic accuracy studies may include one or more comparator tests to 
which the index test is compared. In fully paired direct comparisons, all par-
ticipants receive index test, comparator test(s) and reference test. As an al-
ternative, participants may be randomly allocated to receive the index or the 
comparator test (randomized direct comparison). The comparison is indirect, 
if the estimates of diagnostic accuracy from different study populations are 
compared[27]. 
The identification of sources of bias in diagnostic accuracy studies requires a 
detailed assessment of the study design, including criteria on reference stand-
ard, study population and blinding. 
                                                             
4 For Diagnostic accuracy studies, the terms cohort and case-control study relate to the 
inclusion modes only – in contrast to conventional case-control and cohort studies, they 
are always cross-sectional with the aim to determine a status quo at one timepoint. 
assessment may include 
other research questions: 
prognosis, aetiology, 
diagnostic accuracy 
“single-gate” vs. 
“double-gate” study 
designs 
one or more  
comparator tests 
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 When can diagnostic accuracy be used as surrogate  
for health outcomes? [38, 48] 
 The index test has similar sensitivity as the comparator test but other 
positive attributes such as higher specificity, lower costs, fewer adverse 
events or being less invasive: the value of the test corresponds to the 
benefits of avoiding adverse events or costs associated with the 
comparator test. 
 The index test has higher sensitivity and similar specificity than the 
comparator test and the extra cases detected by the new, more sensitive 
index test represent the same spectrum of disease (size, grade, severity) 
or a same definition of disease for which treatment response is known. 
This condition may e.g. be fulfilled if in clinical diagnostic routine, 
test cases are subsequently confirmed by the reference standard 
(linked-evidence approach5). 
 The index test has higher sensitivity and similar specificity than the 
comparator test and treatment response of the extra cases detected by 
the index test has been shown in trials (linked-evidence approach5). 
 
If the index test is less sensitive or less specific than the comparator test but 
has other positive attributes, assessing the trade-off of benefits and harms of 
using the index test will require direct evidence from an RCT [48]. 
RCTs are also needed if no or only a poor reference standard is available to 
determine diagnostic accuracy or if the index test is expected to perform bet-
ter than the current reference standard, which by definition cannot be demon-
strated in diagnostic accuracy studies. 
 
5.2.2 Prognosis and Aetiology 
A prognostic test is used to predict a patient’s likelihood to experience a medi-
cal event (disease development or progression), within a defined time interval 
and using the observed proportion of the population experiencing this event 
as reference. 
Biomarkers are indicative of a physiological state and therefore not neces-
sarily causal. Cross-sectional studies do not allow for causal inferences to be 
made since in these studies biomarker-disease measurements occur simulta-
neously. In order to show causality and hence, prognostic value, prospective 
cohort studies are required that follow health outcomes over time in a popu-
lation characterised by the levels of the biomarker [11].  
Huguet et al. recently proposed an adaptation of the GRADE framework to 
research on prognostic factors in which they suggest to consider the phase of 
investigation in the ranking of evidence: a high level of evidence for progno-
sis would be provided by prospective or retrospective cohort studies that test 
a fully developed hypothesis and conceptual framework on the underlying 
processes for the prognosis of a health condition[49]. Studies in an early stage 
of investigation, to generate hypotheses, would be attributed a moderate level 
of evidence. 
                                                             
5 See Section 5.2.2 
prognosis:  
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Table 5.2-1: Evidence hierarchies by research questions  
Evidence Level Intervention Diagnostic Accuracy6 Prognosis Screening Aetiology7 
Highest8 I Systematic 
review of Level 
II studies 
Systematic review of  
Level II studies 
Systematic 
review of Level II 
studies 
Systematic 
review of 
Level II 
studies 
Systematic 
review of 
Level II 
studies 
High II RCT  Diagnostic accuracy study9 
Independent blinded 
comparison 
Valid reference standard 
Consecutive patient sample 
Defined clinical presentation 
Prospective 
(inception10) 
cohort studies 
(Phase 2 or Phase 3 
explanatory 
studies) 
RCT Prospective 
cohort study 
Moderate III Non 
randomised 
controlled 
trial/cohort/ 
follow-up study 
Diagnostic Accuracy Study 
not meeting the criteria for 
level II;  
Diagnostic case-control study 
Cohort study 
(Phase 1 
explanatory study) 
or control arm of 
randomised trial 
Non 
randomised 
controlled 
trial/cohort/ 
follow up 
study 
Retrospectiv
e cohort 
study or 
case-control 
study 
Low IV Case series, 
case-control, 
or historically 
controlled 
studies 
Diagnostic Accuracy Study 
with poor reference 
standard;  
study of diagnostic yield 
Case series or 
case control 
studies 
Case series, 
case-control, 
or historically 
controlled 
studies 
Cross-sectional 
study or case 
series 
Source: (adapted from [43, 44, 49]) 
 
  
                                                             
  6 This column only applies to reviews assessing diagnostic accuracy. For the evalua-
tion of the impact of a diagnostic test on health outcomes, the “intervention” column 
should be used. 
  7 This column should only be used if a causal relationship cannot be determined using 
RCT. Otherwise the “intervention” column should be used. 
  8 The highest evidence level applies only to SR of Level II studies. SR of studies from 
other evidence levels should not be ranked higher than the levels of the studies in-
cluded. 
  9 The fulfilment of these criteria can be determined through quality appraisal of the 
diagnostic accuracy study using the QUADAS-2 tool [54] 
10 All persons in an inception cohort are non-diseased or in the same status of the 
disease. 
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5.2.3 Clinical trial designs 
The evaluation of biomarkers used for treatment selection necessarily requires 
a randomised design to isolate the effect of the marker on therapeutic effica-
cy from all the other factors influencing a treatment choice [50]. To this end, 
new trial designs have been proposed, with substantial variability in the la-
belling of the trial designs [51]. Trial designs can be classified according to 
the patient flow in the studies; each category allowing assessing different ef-
fects (Figure 5.2-1).  
 
Targeted or Enrichment designs [51, 52] 
Patients are screened for the presence or absence of the marker and only the 
subgroup of patients defined by a specific marker status is studied (Example: 
HER2/Trastuzumab trial, [53]). The study is powered to detect a clinically 
meaningful effect in the marker-positive subgroup, but does not provide in-
formation on the treatment benefit in the marker-negative group. It therefore 
does not allow to answer the question, whether costs and inconvenience as-
sociated with biomarker-based treatment allocation is worthwhile [52]. Fur-
thermore causality of any association of treatment effect with biomarker sta-
tus may not be established, as there is no comparison with a biomarker nega-
tive group (Table 5.2-2). 
Alternatively, marker-negative patients may be assigned a control treatment 
– this form of hybrid design was used for example in the TAILORx trial for 
the evaluation of Oncotype DX [54]. 
 
Marker by treatment interaction design  
or tests at baseline in RCT [17, 55, 56] 
All patients are randomly assigned to treatments based on a randomisation 
that may or may not be stratified based on biomarker status. This is the most 
efficient trials design in situations in which there are two or more existing 
treatment options with no definitive evidence for one being preferred in a giv-
en population [57]. 
This design allows the embedment of the evaluation of various diagnostic 
strategies in classical intervention studies. To this end, either before or after 
randomisation, all study participants are tested with one or more diagnostic 
test strategies (e.g. biomarker-based and non-marker based/standard). Then 
all participants are randomised to either of two treatments: this randomisa-
tion should ideally be blinded and independent of test results. In principle 
this study design may also be performed retrospectively in archived samples 
of a classical intervention study of the treatment under consideration, provid-
ed that the standard diagnostic treatment decision can be determined retro-
spectively [56]. Retrospective stratification, however, involves a higher risk 
of bias by confounding. A stratified randomisation by biomarker will ensure 
appropriate power of the study and minimise selection bias. Because all pa-
tients are randomised to both treatment and control, this study design is also 
designated “randomize-all”.  
With randomisation stratified according to biomarker status, this study design 
allows to assess the relationship between the test (biomarker) and the treat-
ment, i.e. whether the biomarker is predictive (modifier of treatment effect) 
or prognostic (favourable outcome in marker-positive patients regardless of 
treatment) (Table 5.2-2). 
isolate the effect of the 
marker on therapeutic 
efficacy from all the 
other factors influencing 
a treatment choice 
only the subgroup  
of patients defined by  
a specific marker status 
is studied 
all patients randomly 
assigned to treatments  
 
randomisation may or 
may not be stratified 
based on biomarker 
status 
 
“Randomise-all” 
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Biomarker strategy designs [17, 58]  
In this design, marker status is first determined in all patients, and then pa-
tients are randomised to either a biomarker-based or a biomarker-independ-
ent strategy for allocation of treatment. The biomarker-independent strategy 
may be a standard diagnostic pathway or a randomised treatment allocation. 
This type of trial design allows to directly comparing the outcome of all pa-
tients in the marker-based arm to the outcome of the patients in the non-
marker based arm. The efficiency of this trial design is limited by the fact 
that in many cases treatment choices by either diagnostic strategy would be 
the same for a large number of the patients, reducing the potential observable 
differences between the groups and thus increasing the required participants 
number [50]. This study design allows to directly comparing the potential of 
two diagnostic strategies to differentiate between patients likely to profit and 
patients unlikely to profit of a specific treatment. This study design does not 
allow to assess the relationship between the test (biomarker) and the treat-
ment: i.e. whether the biomarker is predictive (modifier of the treatment ef-
fect) or prognostic (favourable outcome in marker-positive patients regardless 
of treatment) [59] (Table 5.2-2). 
 
RCT of discordant test results[55, 56] 
This is an adaptation of the marker-based strategy design, enriching on the 
fraction of participants that receive discordant results using the two diagnos-
tic strategies, sparing a treatment randomisation to those in which both diag-
nostic strategies come to the same treatment decision. 
All participants are tested with both strategies, only those with discordant test 
results are randomised to the treatment options under consideration. In both 
groups (new +/standard –) and (new –/standard +) superiority (or: non-infe-
riority) of the treatment chosen by the biomarker based strategy over the treat-
ment option chosen by standard diagnosis needs then to be demonstrated [56] 
(Table 5.2-2). 
 
Double-randomised controlled trial 
This design combines a randomisation to the testing strategy, similar to the 
biomarker-strategy design, with a randomisation to the treatment in both bio-
marker positive and negative groups to allow to explain the biomarker-drug 
relationship (i.e. predictive vs. prognostic factor) [9] (Table 5.2-2). This design 
poses practical limitations, especially if the biomarker is uncommon. Ethical 
challenges might arise if a new treatment is tested as a replacement for an 
old therapy and an effect is only plausible in biomarker-positive patients: in 
this case it might be considered unethical to randomise biomarker-negative 
patients to a treatment, where no effect is to expected, while forgoing an ef-
fective treatment [9], which is also of concern for the marker by treatment 
interaction design. 
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Table 5.2-2: List of effects that can be assessed and questions that can be answered by the trials of each design category  
  Marker by 
treatment 
Biomarker-
strategy 
  
Questions trial can answer  
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Treatment effects      
Q1. How does the experimental treatment compare with 
the control treatment in biomarker-positives?  
✓ ✓ ✓ — ✓ 
Q2. How does the experimental treatment compare with 
the control treatment in biomarker-negatives?  
— ✓ ✓ — ✓ 
Q3. How does the experimental treatment compare with 
the control treatment in overall study population?  
— ✓ ✓ — ✓ 
Biomarker effects      
Q4. Is the biomarker status associated with the outcome 
in the standard of care group? (Is the biomarker 
prognostic?)  
— ✓ ✓ — ✓ 
Q5. Is the biomarker status associated with the outcome 
in the experimental treatment group?  
— ✓ ✓ — ✓ 
Biomarker by treatment effect      
Q6. Is the biomarker status associated with a benefit of 
experimental treatment? (Is the biomarker is 
predictive?)  
— ✓ ✓ — ✓ 
Strategy effects   ✓  ✓ 
Q7. How does the biomarker-based treatment strategy 
compare with the control treatment in the overall 
study population?  
— ✓ Indirect ✓ ✓ ✓ 
Q8. How does the biomarker-based treatment strategy 
compare with the experimental treatment in the 
overall study population?  
— ✓ Indirect ✓ ✓ ✓ 
Source: (adapted from [51]) 
 
 For a classification of varying labels used by study authors, see [51].  
 For a comparison of which research questions can be answered by 
which trial design, see [57] or [51]. 
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Figure 5.2-1: Randomised clinical trial designs for biomarker evaluation  
Source: [17, 51, 56, 59] 
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6 Critical appraisal 
6.1 Internal validity 
Internal validity describes how well the design and conduct of the study min-
imises potential biases, i.e. the risk of bias resulting from “study limitations” 
[60] or “study quality”. Other possible sources of bias, such as inadequate re-
porting or publication bias are discussed later. Different checklists apply to 
the assessment of internal validity of different study designs. Reviewers should 
define a priori the relevant quality criteria. Explicit rules for rating each qual-
ity criterion adapted to the specific review question and definitions for rank-
ing the overall risk of bias as “High”, “Low” or “Unclear” should be provided. 
The appraisal should not follow an automatised scoring process using prede-
fined values for each criterion or a point system, rather risk assessment will 
require a thoughtful approach about the methodological issues and the direc-
tion of the potential bias [2].  
Internal validity criteria may come into play at several time points during the 
assessment: either as inclusion/exclusion (“fatal flaw”) criteria in the initial 
or a secondary screening of eligible articles, or as exclusion criteria before 
proceeding to the evidence synthesis, or quality criteria may be used to test 
the association between quality and outcomes. Adequate reporting is condi-
tional for quality appraisal, but it is in itself not yet a quality criterion [60].  
Standard internal validity critical appraisal checklists for randomised con-
trolled trials and cohort studies for interventions may be used [2]. In the fol-
lowing we will present quality checklists for the special cases of diagnostic 
accuracy and prognosis studies. 
 
6.1.1 Diagnostic accuracy studies 
Diagnostic accuracy relates to the strength of association between the results 
of the index test and a reference standard (or „gold standard“, meaning the 
best available diagnostic approach).  
All sources of bias particularly common to diagnostic accuracy studies have 
been comprehensively reviewed by Whiting et al. [61] and, based on these re-
sults, the QUADAS-2 checklist has been developed to assess the main empiri-
cally validated sources of bias in Diagnostic accuracy studies [62] (Table 
6.1-1).  
  
how well the design  
and conduct of the 
study minimises 
potential biases 
quality checklist for 
diagnostic accuracy: 
QUADAS-2 to assess 
bias introduced by ... 
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Table 6.1-1: QUADAS-2 Checklist for assessment of Risk of Bias in Diagnostic Accuracy Studies 
Domain 1: Patient selection 
Was a consecutive or random sample of patients enrolled? Yes   No   Unclear  
Was a case-control design avoided? Yes   No   Unclear  
Did the study avoid inappropriate exclusions? Yes   No   Unclear  
Could the selection of patients have introduced bias? Risk: Low   High   Unclear  
Domain 2: Index test(s) (complete for each index test used) 
Were the index test results interpreted without knowledge of the reference standard? Yes   No   Unclear  
If a threshold was used, was it pre-specified? Yes   No   Unclear  
Could the conduct or interpretation of the index test have introduced bias? Risk: Low   High   Unclear  
Domain 3: Reference Standard 
Is the reference standard likely to correctly classify the target condition? Yes   No   Unclear  
Were the reference results interpreted without knowledge of the results  
of the index test? 
Yes   No   Unclear  
Could the reference standard, its conduct, or its interpretation have introduced bias? Risk: Low   High   Unclear  
Domain 4: Flow and Timing 
Was there an appropriate interval between index test(s) and reference standard? Yes   No   Unclear  
Did all patients receive a reference standard? Yes   No   Unclear  
Did all patients receive the same reference standard? Yes   No   Unclear  
Were all patients included in the analysis? Yes   No   Unclear  
Could the patient flow have introduced bias? Risk: Low   High   Unclear  
Source: [62] 
 
We have previously explained that a “Two-gate” study design, or “diagnostic 
case-control” study design is prone to spectrum bias, which is reflected in the 
questions regarding “Patient selection”, in this case reviewers would need to 
estimate if despite the case control design the full spectrum of disease and 
non-disease is represented. 
The appropriate interval between index test(s) and reference standard needs 
to be defined in context with the review question. There is risk of bias, if: 
 Interventions have been initiated between index test and reference 
standard and it cannot be excluded that they have (already) influenced 
the condition of the participant at the time of conduct of the reference 
standard.  
 It cannot be excluded that the condition of the participant has signif-
icantly improved (e.g. clearance of an infection) or worsened (e.g. tu-
mour progression) in the time interval chosen 
 It cannot be ascertained that the reference standard can detect the 
condition after the time interval chosen (e.g. motor symptoms of mul-
tiple sclerosis)  
 
 
 
 
 
... patient selection 
... flow and timing 
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Per definition diagnostic accuracy is inferred from the comparison of the in-
dex test with a reference test, which for this purpose is considered „ideal“, 
i.e. able to detect “true” presence or absence of disease. As a consequence of 
this assumption, estimates of diagnostic accuracy are not possible or potential-
ly biased if 
 No reference standard is available 
 Available reference standards are known to be imperfect 
 Not all participants receive the same reference standard  
(Differential verification bias) 
 Not all participants receive a reference standard  
(Partial verification bias) 
 Interpretation of the results of index test or reference test is not 
blinded to the results of the other test respectively (Review bias). 
There is no consensus how to process indeterminate results. Often these re-
sults are either excluded or classified as positive – both procedures may lead 
to overestimation of test performance. It is recommended to classify indeter-
minate results by “intention to diagnose”: i.e. false negative if the reference 
standard result is positive and false positive if the reference standard result 
is negative [63, 64]. 
Table 6.1-2: Classification of indeterminate results by “Intention to Diagnose” 
 Reference standard 
+ - 
In
d
ex
 t
es
t 
+ 
True Positive  
A 
False Positive 
B 
? 
Indeterminate  
(RS Positive)  
 Indeterminate  
(RS Negative) 
- False Negative 
C 
True Negative 
D 
Source: [63, 64] 
 
6.1.2 Prognosis studies 
In a systematic review Hayden et al. have identified quality items used in as-
sessing 6 sources of bias in prognosis studies: study participation, study at-
trition, measurement of prognostic factors, measurement of and controlling 
for confounding variables, measurement of outcomes and analysis approach-
es [65].  
Based on this work, a team of epidemiologists, statisticians and clinicians de-
veloped the QUIPS (Quality in Prognosis Studies) tool for assessing bias in 
studies of prognostic factors which demonstrated acceptable reliability [66] 
and so far is the only tool available for this purpose (Table 6.1-3).  
The authors reported reasonable interrater agreement scores for the bias do-
mains 1-4 and 6, but a κ statistic of only 0.4 for the domain 5 (Study confound-
ing). As a consequence they recommend operationalising the tool a priori by 
including specifying key characteristics and omitting items irrelevant for the 
review question (marked with LIST in Table 6.1-3). 
 
... reference standard 
and index test 
indeterminate results 
need to be classified 
quality checklist for 
prognosis studies: 
QUIPS 
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Table 6.1-3: QUIPS tool for the assessment of bias in studies of prognostic factors 
Biases Issues to consider for judging overall rating of "Risk of bias"  
Domain 1: Study Participation 
Goal: To judge the risk of selection bias (likelihood that relationship between prognostic factor and outcome is 
different for participants and eligible non-participants). 
Source of target 
population 
The source population or population of interest is adequately 
described for key characteristics (LIST). 
Yes   Partial   
No   Unclear  
Method used to 
identify population 
The sampling frame and recruitment are adequately described, 
including methods to identify the sample sufficient to limit potential 
bias (number and type used, e.g., referral patterns in health care) 
Yes   Partial   
No   Unclear  
Recruitment period Period of recruitment is adequately described Yes   Partial   
No   Unclear  
Place of recruitment Place of recruitment (setting and geographic location) are 
adequately described 
Yes   Partial   
No   Unclear  
Inclusion and 
exclusion criteria 
Inclusion and exclusion criteria are adequately described  
(e.g., including explicit diagnostic criteria or “zero time” description). 
Yes   Partial   
No   Unclear  
Adequate study 
participation 
There is adequate participation in the study by eligible individuals Yes   Partial   
No   Unclear  
Baseline 
characteristics 
The baseline study sample (i.e., individuals entering the study) is 
adequately described for key characteristics (LIST). 
Yes   Partial   
No   Unclear  
Summary Study 
participation 
The study sample represents the population of interest on key 
characteristics, sufficient to limit potential bias of the observed 
relationship between PF and outcome. 
Risk: High  
Moderate   Low  
Domain 2: Study Attrition 
Goal: To judge the risk of attrition bias (likelihood that relationship between PF and outcome are different for 
completing and non-completing participants). 
Proportion of baseline 
sample available for 
analysis 
Response rate (i.e., proportion of study sample completing the study 
and providing outcome data) is adequate. 
Yes   Partial   
No   Unclear  
Attempts to collect  
information on partici-
pants who dropped out 
Attempts to collect information on participants who dropped out of 
the study are described. 
Yes   Partial   
No   Unclear  
Reasons and potential 
impact of subjects lost 
to follow-up 
Reasons for loss to follow-up are provided. Yes   Partial   
No   Unclear  
Outcome and 
prognostic factor 
information on those 
lost to follow-up 
Participants lost to follow-up are adequately described for key 
characteristics (LIST). 
Yes   Partial   
No   Unclear  
There are no important differences between key characteristics (LIST) 
and outcomes in participants who completed the study and those 
who did not. 
Yes   Partial   
No   Unclear  
Study Attrition 
Summary  
Loss to follow-up (from baseline sample to study population 
analysed) is not associated with key characteristics (i.e., the study 
data adequately represent the sample) sufficient to limit potential 
bias to the observed relationship between PF and outcome.  
Risk: High  
Moderate   Low  
Domain 3: Prognostic Factor Measurement 
Goal: To judge the risk of measurement bias related to how PF was measured  
(differential measurement of PF related to the level of outcome). 
Definition of the PF A clear definition or description of 'PF' is provided (e.g., including 
dose, level, duration of exposure, and clear specification of the 
method of measurement). 
Yes   Partial   
No   Unclear  
Valid and Reliable 
Measurement of PF 
Method of PF measurement is adequately valid and reliable to limit 
misclassification bias (e.g., may include relevant outside sources of 
information on measurement properties, also characteristics, such as 
blind measurement and limited reliance on recall). 
Yes   Partial   
No   Unclear  
Continuous variables are reported or appropriate cut-points (i.e., not 
data-dependent) are used. 
Yes   Partial   
No   Unclear  
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Biases Issues to consider for judging overall rating of "Risk of bias"  
Method and Setting 
of PF Measurement 
The method and setting of measurement of PF is the same for all 
study participants. 
Yes   Partial   
No   Unclear  
Proportion of data on 
PF available for analysis 
Adequate proportion of the study sample has complete data for  
PF variable. 
Yes   Partial   
No   Unclear  
Method used for 
missing data 
Appropriate methods of imputation are used for missing 'PF' data. Yes   Partial   
No   Unclear  
PF Measurement 
Summary  
PF is adequately measured in study participants to sufficiently limit 
potential bias. 
Risk: High  
Moderate   Low  
Domain 4: Outcome Measurement 
Goal: To judge the risk of bias related to the measurement of outcome  
(differential measurement of outcome related to the baseline level of PF). 
Definition of the 
Outcome 
A clear definition of outcome is provided, including duration of 
follow-up and level and extent of the outcome construct. 
Yes   Partial   
No   Unclear  
Valid and Reliable 
Measurement of 
Outcome 
The method of outcome measurement used is adequately valid and 
reliable to limit misclassification bias (e.g., may include relevant 
outside sources of information on measurement properties, also 
characteristics, such as blind measurement and confirmation of 
outcome with valid and reliable test). 
Yes   Partial   
No   Unclear  
Method and Setting 
of Outcome 
Measurement 
The method and setting of outcome measurement is the same for  
all study participants. 
Yes   Partial   
No   Unclear  
Outcome 
Measurement 
Summary 
Outcome of interest is adequately measured in study participants  
to sufficiently limit potential bias. 
Risk: High  
Moderate   Low  
Domain 5: Study Confounding 
Goal: To judge the risk of bias due to confounding  
(i.e. the effect of PF is distorted by another factor that is related to PF and outcome). 
Important 
Confounders 
Measured 
All important confounders, including treatments (key variables in 
conceptual model: LIST), are measured. 
Yes   Partial   
No   Unclear  
Definition of the 
confounding factor 
Clear definitions of the important confounders measured are 
provided (e.g., including dose, level, and duration of exposures). 
Yes   Partial   
No   Unclear  
Valid and Reliable 
Measurement of 
Confounders 
Measurement of all important confounders is adequately valid and 
reliable (e.g., may include relevant outside sources of information  
on measurement properties, also characteristics, such as blind 
measurement and limited reliance on recall). 
Yes   Partial   
No   Unclear  
Method and Setting 
of Confounding 
Measurement 
The method and setting of confounding measurement are the same 
for all study participants. 
Yes   Partial   
No   Unclear  
Method used for 
missing data 
Appropriate methods are used if imputation is used for missing 
confounder data. 
Yes   Partial   
No   Unclear  
Appropriate 
Accounting for 
Confounding 
Important potential confounders are accounted for in the study 
design (e.g., matching for key variables, stratification, or initial 
assembly of comparable groups). 
Yes   Partial   
No   Unclear  
Important potential confounders are accounted for in the analysis 
(i.e., appropriate adjustment). 
Yes   Partial   
No   Unclear  
Study Confounding 
Summary  
Important potential confounders are appropriately accounted for, 
limiting potential bias with respect to the relationship between PF 
and outcome. 
Risk: High  
Moderate   Low  
Domain 6: Statistical Analysis and Reporting 
Goal: To judge the risk of bias related to the statistical analysis and presentation of results. 
Presentation of 
analytical strategy 
There is sufficient presentation of data to assess the adequacy  
of the analysis. 
Yes   Partial   
No   Unclear  
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Biases Issues to consider for judging overall rating of "Risk of bias"  
Model development 
strategy 
The strategy for model building (i.e., inclusion of variables in the 
statistical model) is appropriate and is based on a conceptual 
framework or model. 
Yes   Partial   
No   Unclear  
The selected statistical model is adequate for the design  
of the study. 
Yes   Partial   
No   Unclear  
Reporting of results There is no selective reporting of results. Yes   Partial   
No   Unclear  
Statistical Analysis 
and Presentation 
Summary 
The statistical analysis is appropriate for the design of the study, 
limiting potential for presentation of invalid or spurious results. 
Risk: High  
Moderate   Low  
Source: [66] 
 
 
6.2 Strength of the body of evidence 
Following the assessment of the single studies, the whole body of evidence rel-
evant to the research question, is assessed in the context of the setting in which 
it is to be applied, now per outcome and across studies [35]. 
For the evaluation of the strength of evidence using GRADE, a starting level 
of evidence is attributed based on the study design, which is then modified by 
five potentially downgrading factors (study limitations, consistency, directness, 
precision, publication bias) and three potentially upgrading factors (strength 
of association, exposure-response gradient, plausible confounding) [67]. 
For research questions on interventions, GRADE attributes a starting level 
of evidence based on the research design – ranking RCT as “High” and ob-
servational studies as “Low”. As outlined in Section 4.2 of this report, under 
specific circumstances alternative evidence hierarchies should be considered 
(Table 5.2-1) [49]. In the following we summarize proposed adaptations of the 
GRADE framework to the special cases of diagnostic accuracy studies and 
prognosis studies. 
 
6.2.1 Adaptations of the GRADE framework 
to diagnostic accuracy and prognosis studies 
Diagnostic accuracy studies 
Study limitations are identified based on the quality assessment of the single 
studies; the same rules as for grading of interventions apply to the overall 
grading of study limitations in a body of evidence [60].  
Directness. An important challenge is to decide on whether diagnostic accu-
racy alone, a linked evidence approach or direct evidence from RCT is need-
ed to answer the specific review question [68]. It being in most cases the only 
evidence available, it is tempting to use diagnostic accuracy as a surrogate 
outcome for patient outcomes. The linkage between diagnostic accuracy and 
clinical outcomes, however, is in most cases indirect and is challenging to es-
tablish. 
 
strength of whole body 
of evidence according  
to GRADE 
appropriate evidence 
hierarchy dependent of 
review question 
study limitations 
directness:  
direct or indirect 
evidence needed for 
review question 
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Scenario 1. In Section 5.2 we have described the conditions under which diag-
nostic accuracy alone can be used as surrogate outcome for clinical outcomes. 
In this case the evidence hierarchy (Table 5.2-1) and the risk of bias assess-
ment tool for diagnostic accuracy studies (Table 6.1-1) should be applied to 
determine the starting level of evidence and potential study limitations.  
Scenario 2. Section 5.2 further describes the conditions in which diagnostic 
accuracy may be used as intermediate outcome in a “linked evidence” ap-
proach. This approach would require separate grading of the body of evidence 
for each link in the chain (based on the analytical framework established, see 
Section 3.1).  
If the conditions for Scenario 1 and 2 are fulfilled, grading of the body of ev-
idence from diagnostic accuracy studies would NOT require a downgrading 
for indirectness. 
If however, the research question necessitates direct evidence from RCT, ev-
idence from studies on diagnostic accuracy would need to be downgraded for 
indirectness. 
According to GRADE, indirectness also includes an assessment of applica-
bility (of the results). For diagnostic accuracy studies, this is evaluated using 
the QUADAS-2 tool [62]. Investigators need information on inclusion and ex-
clusion criteria, settings and locations of data collections, methods of patient 
recruitment and sampling to decide whether evidence about the test is valid, 
clinically relevant and applicable to specific patient groups or individuals [45]. 
Table 6.2-1: QUADAS-2 checklist for the assessment of applicability in diagnostic accuracy studies 
Domain 1: Patient selection 
Describe included patients (prior testing, presentation, intended use of index test  
and setting) 
 
Is there concern that the included patients do not match the review question? Low   High   Unclear  
Domain 2: Index test(s) (complete for each index test used) 
Describe the index test and how it was conducted and interpreted.  
Is there concern that the index test, its conduct, or interpretation differ from the 
review question? 
Low   High   Unclear  
Domain 3: Reference Standard 
Describe the reference standard and how it was conducted and interpreted.  
Is there concern that the target condition as defined by the reference standard does 
not match the review question? 
Low   High   Unclear  
Source: [62] 
 
Guyatt et al. [69] describe the process of evaluating inconsistency in interven-
tion studies. Importantly, this article applies (only) to binary/dichotomous 
outcomes and relative, not absolute measures of effect. Instead of forest plots, 
the most common representation format of diagnostic test performance to al-
low detection of inconsistency is a summary receiver operating characteristic 
(ROC) curve [70], displaying sensitivity and specificity results from various 
studies. This can be complemented by a bubble plot of true positive versus 
false positive rates spread in ROC space. [68]. Reviewers should seek to re-
solve inconsistency through a critical consideration of possible explanations 
(differences in populations, interventions or outcomes) for any detected incon-
sistency.  
scenario 1:  
conditions for use of 
diagnostic accuracy 
alone 
scenario 2:  
conditions for use of 
diagnostic accuracy  
in linked-evidence 
approach 
ROC plot to assess 
inconsistency in 
diagnostic accuracy 
studies 
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Imprecision and Publication bias are defined and assessed as for interven-
tion studies [71, 72]. The impact of imprecision on clinical outcomes may be 
determined by calculating post-test probabilities. In contrast to clinical trials, 
there is no register for diagnostic accuracy studies. In adaptation of an ap-
proach for prognostic studies, one possibility is to generally assume that pub-
lication bias is present, except if a diagnostic test has been studied in a large 
number of diagnostic accuracy studies [49].  
A dose response association might be observed for tests with continuous out-
comes and multiple cut-offs. Inconsistency therefore may arise from test thresh-
olds/cut-offs for positive/negative categorisation varying across test accuracy 
studies.  
Plausible unmeasured confounders. The strength of evidence is increased if, 
despite plausible confounders that would decrease the diagnostic accuracy, the 
diagnostic accuracy measured is high. 
In intervention studies, strength of association may lead to upgrading of the 
strength of evidence, if an observed association is large enough that it cannot 
have occurred solely as a result of bias from confounding factors [68]. For di-
agnostic accuracy studies, this domain can be applied for upgrading of the ev-
idence when diagnostic accuracy of an index test is measured with an imper-
fect reference standard and hence may be under-estimated [68]. 
The presumed consequences of classification in each of the categories (FP, 
TP, FN, TN) need to be defined (see example in Table 6.2-2) and the direct-
ness of the link assessed. Benefits of correct classification should outweigh the 
harms of misclassification. This assessment should also include consequences 
of inconclusive results [30]. 
Table 6.2-2: Tabular presentation of the changes in classification induced by a new test compared to standard strategy – 
Example: p16/Ki-67 triage compared with direct referral to colposcopy 
Putative 
benefit of 
new test 
Sensitivity Specificity TP TN FP FN 
Inconclusive 
results 
Simpler, 
less time 
lower higher     Unknown 
Benefits and harms from  
changes in classification 
Benefit 
from 
treatment 
Benefit from 
avoiding 
unnecessary 
tests 
Anxiety and 
morbidity 
from 
unnecessary 
additional 
testing and 
treatment 
Possible 
detriment from 
delayed 
diagnosis 
Benefit from 
treatment, 
anxiety and 
morbidity from 
unnecessary 
testing and 
treatment 
Certainty/Uncertainty  
of the benefits/harms 
No 
uncertainty 
Major 
uncertainty 
(not clear if 
clinicians would 
trust test 
results) 
No 
uncertainty 
Major 
uncertainty 
(impact of 
negative result 
on screening 
attendance 
unclear 
No uncertainty 
(all cases will 
be confirmed 
by colposcopy 
+/- biopsy) 
 
 
 
Post-test probabilities  
to assess imprecision 
upgrading possible  
in case of imperfect 
reference standard 
classification of 
consequences according 
to TN, FN, TP,  
FP categories 
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Prognosis studies 
An adaptation of the GRADE Framework for prognostic studies has been 
proposed by Huguet et al. [49].  
Study limitations for prognostic studies are assessed based on the quality ap-
praisal of the single studies (Section 6.1.2). 
Reviewers should downgrade for inconsistency if estimates of the prognostic 
factor association with the outcome vary in direction and there is no or min-
imal overlap of the confidence intervals. If a meta-analysis is conducted, be-
fore downgrading for inconsistency, a subgroup analysis in a priori defined 
subgroups (e.g. differences in population, duration of follow-up, study meth-
ods) should be performed [49]. 
Indirectness may be present if the study population does not represent the 
population of the review question (e.g. patients of a headache clinic versus 
general population) [49]. Similarly, downgrading for indirectness would be 
justified if the prognostic factor or the outcomes assessed would not represent 
the full bandwidth of the review question. 
Of particular importance in the review of prognostic studies is publication 
bias. In contrast to clinical trials, there is no register for prognostic research 
studies. One possibility therefore is to generally assume that publication bias 
is present, except if a prognostic factor has been studied in a large number of 
cohort studies [49].  
Other domains are assessed as for intervention studies, with the exception of 
plausible confounders: in contrast to intervention studies, the effect of inad-
equate control of confounding on the study effects are unclear and as such 
cannot be taken into account to estimate the accuracy of the effect estimate. 
Risk of bias by confounding, however, is covered by the quality appraisal of 
the single studies [49]. 
 
6.2.2 Assessment of co-dependent technologies 
Decisions on reimbursement and/or implementation in clinical practice of new 
technologies require evidence on the clinical benefit in terms of patient health 
outcomes.  
Biomarker tests are not stand-alone technologies but need to be assessed with 
regards to patient management changes and treatment incited by the test re-
sults. This poses several evidentiary challenges, notably a lack of (direct) evi-
dence from randomised controlled trials (see Sections 3.4 and 5.2) as discussed 
for example in [73]. To reduce decision-making uncertainty in the absence 
of direct evidence, a linked-evidence approach for the assessment of medical 
tests was first proposed in the Australian guidance for the assessment of di-
agnostic tests [8] and mentioned in several international guidelines on diag-
nostics evaluation [3, 5, 12, 57]; while other institutions do not include it as 
an option [7]. Linked evidence describes a chain of arguments linking differ-
ent types of evidence, provided that a) data are transferrable across different 
parts of the linkage and b) for each element, evidence is gathered systemati-
cally and transparently and is considered internally valid. 
A framework for evaluating evidence on the clinical benefit of co-dependent 
technologies for reimbursement decisions has recently been published [9]. 
In the following we will present a generalised summary of this approach. 
adaptation of  
GRADE framework  
to prognosis studies 
framework for 
evaluating evidence  
on the clinical benefit  
of co-dependent 
technologies for 
reimbursement 
decisions 
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Predictive biomarkers 
Predictive biomarkers guide treatment choices: a drug A is expected to per-
form better than a drug B in biomarker-positive patients, while no differences 
of treatment effect are expected in biomarker-negative patients. 
Table 6.2-3: Differentiation of biomarker types by impact on health outcomes 
 Outcome Biomarker + Biomarker - 
  Drug A Drug B Drug A Drug B 
Predictive Overall survival 60% 30% 30% 30% 
RR 2.0  1.0  
Prognostic Overall survival 70% 60% 35% 30% 
RR 1.2  1.2  
Both Overall survival 60% 40% 20% 20% 
RR 1.5  1.0  
Source: [9] 
 
In a first step, the biological plausibility of the relationship between the drug 
and the biomarker is evaluated: evidence must be presented that the biomark-
er is predictive (treatment effect modifier) or prognostic (indicative of disease 
progression independent of treatment) or both. Only double randomised trials 
or trials with a marker by treatment interaction design (Section 5.2) allow an 
answer to this question; the relationship cannot be clarified by a marker strat-
egy design. If the biomarker is a prognostic factor, other treatments will also 
be likely to have a favourable outcome in the marker positive subgroup and 
should be included in the comparison [9]. 
Highest level of evidence on the clinical benefit of a test and treatment strat-
egy is provided by a double randomised controlled trial, with one randomi-
sation to the testing strategy and a second randomisation to treatment and 
control. Direct evidence, albeit of a lower level, can also be provided by trials 
with a marker strategy design or a biomarker by treatment design (see Sec-
tion 5.2) [9].  
If direct evidence is not available, there are various options to provide linked-
evidence. Here we describe a few examples [9]: 
Option A: A marker by treatment design is linked to a randomised controlled 
trial of the same treatment/control in an untested population, thereby allow-
ing comparing the relative effectiveness of treatment versus control in a bio-
marker stratified versus a biomarker un-stratified population. 
Option B: A variation of Option A, where only patients with discordant results 
in a standard testing strategy vs a biomarker based strategy are randomised 
to treatment/control and compared to the RCT in an untested population. 
Option C: Patients in the standard and the treatment arm of an RCT are ret-
rospectively analysed for marker status or tests are performed in archived 
samples. Relative effectiveness of treatment versus control is then compared 
to a biomarker-positive population in an enrichment design. Test accuracy 
serves as an additional link in this option. 
 
assess biological 
plausibility of the 
relationship between 
the drug and the 
biomarker 
assess ability  
of a test and treatment 
combination to improve 
patient outcomes:  
Table 8.2-1 
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Diagnostic and prognostic biomarkers 
Diagnostic and prognostic biomarkers are not co-dependent technologies with 
a specific treatment. Nevertheless, they cannot provide clinical benefit with-
out inducing patient management changes and treatment decisions compared 
to the established test and treatment strategy. Specific challenges here are to 
identify (pragmatic) RCT reflecting the population and clinical practice in the 
country/health system in which the biomarker is intended to be introduced [9]. 
 
 For details on the analytical framework to assess co-dependent 
technologies, see [9]. To assess the ability of a test and treatment 
combination to improve patient outcomes  
(Qualification 2 in Table 3.4-1), see [9] or Table 8.2-1 in the Annex. 
 
 
need for  
pragmatic RCT 
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8 Annexes 
8.1 Formulation of review question: Checklist to assess 
context of submission and impact on clinical practice 
Table 8.1-1: Checklist – rationale for co-dependent relationship between test (T) and drug (D).  
(O) – overlap between test and drug.  
Context for the submission  
1) (T) Who is the test sponsor?  Identify the source of the test (e.g. commercial sponsor, research laboratory, 
widespread pathology practice). This includes clinical sponsors of tests, given 
that tests not only guide the initiation of therapy but also the cessation of 
therapy. 
2) (D) Who is the drug sponsor?  This enables a different sponsor to be identified if necessary for each 
component of a pair of co-dependent technologies. 
3) (D) What is the proposed drug?  Provide a description of the drug, its background, mechanism of action, etc. 
Specify the drug’s registration status. 
4) (O) What is the biomarker?  This initial scenario considers genetic DNA biomarkers only, i.e. the assessment 
of one genetic locus at a time. Note that the Food and Drug Administration 
(FDA) in the United States of America has provided specific definitions of 
genomic biomarkers (i.e. assessment across the genome, testing hundreds or 
thousands of loci simultaneously). Genomic testing is beyond this initial 
scope and would be applicable to more complex scenarios. 
5) (T) What is the proposed test?  This relates to a description of a single test or assay. However, often tests  
are done in series when assessing genetic biomarkers or there may be an 
algorithm-based computation of the results of a number of tests. Describe 
the test method in sufficient detail that a laboratory technician would be 
able to perform it. Specify the range of techniques available to measure the 
biomarker (e.g. polymerase chain reaction (PCR), high resolution melting 
(HRM)), and indicate which method, if any, is regarded as the reference or 
'gold' standard. 
6) (T & D) Is the test (or drug) 
currently reimbursed?  
Describe current reimbursement arrangements for the test and the drug.  
This determines the extent of information needed for the current technology. 
7) (T & D) What is the medical 
condition or problem being 
managed, i.e. the patient indication?  
Describe the patient indication being addressed. If different test result 
thresholds are likely, or if eligibility for the drug is determined subjectively, 
consider providing alternative indications. 
8) (O) Is there a clear definition of 
the biomarker(s) (e.g. specific 
genetic DNA mutation(s))?  
Describe the nature of the genetic DNA biomarker (e.g. single nucleotide 
polymorphisms (SNPs), mutation, or copy number variation (CNV)).  
Where relevant, include the following elements describing the context for a 
biomarker: (i) the general clinical area, (ii) the specific use of the biomarker, 
and (iii) the critical parameters which define when and how the biomarker 
should be used. Describe exactly what the test is identifying in cases where 
there is no “specific mutation”, e.g. an expression micro-array of tumour 
tissue which identifies cancer with activation of a particular pathway, and 
susceptibility to a certain drug, but does not identify a specific mutation as 
such. Categorise the mutation as either a germline or somatic mutation.  
If the mutation is classified as a germline mutation, then consider issues 
related to heritability, e.g. testing of relatives and genetic counselling would 
need to be considered and assess the ethical and medico‐legal implications of 
testing. 
9) (O) What is the biological 
rationale for targeting that 
biomarker(s) with the drug?  
Present the initial evidence that was relied on to select the biomarker. 
Describe and explain the overall approach to the selection of the biomarker 
including methods and relevant aspects of study design and statistical analysis. 
Describe the rationale for the selection of the population sample studied in 
the biomarker qualification. Present the criteria used for selection of candidate 
genes (e.g. candidate by position, by function, based on expression profiling 
data). Justify, using molecular biological or pharmacological principles, the 
plausibility of treatment effect modification (or interaction) between the 
biomarker itself and the drug, or alternatively between the drug and another 
factor for which the biomarker is a proxy. Advise whether this rationale 
precedes the specification of the data collection which forms the primary 
source of evidence. 
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10) (O) Do any other biomarker(s) 
predict variation in the comparative 
treatment effect (between using the 
drug and not using the drug)? In the 
case of another biomarker that is a 
genetic mutation:  
• Have details on the specific 
mutation and the nature of the 
mutation been provided?  
• Is the effect of treatment on this 
other mutation consistent with the 
effect under consideration?  
(Note that this may be relevant even if the other biomarker(s) are claimed, 
but are not proven and/or are not reimbursed.) If testing for other biomarkers 
is reimbursed, this would move to a more complex scenario. 
11) (O) What is the prevalence of a 
true positive biomarker in the 
population likely to receive the test?  
The source population would be those who are eligible according to the 
requested reimbursement descriptor and follow the corresponding clinical 
pathway to the point of being offered the test – or the drug in the absence of 
the test. An estimate of the prevalence of a true positive biomarker is relevant 
to calculating the performance of a test in terms of its negative and positive 
predictive value. Indicate where there is no 'gold' standard to determine this 
true positive status of the biomarker and use an alternative appropriate 
methodology to estimate it. Proposed impact on current clinical practice 
Proposed impact on current clinical practice 
12) (T & D) What are the relevant 
clinical pathways? That is, is there a 
description and comparison of the 
proposed clinical management of a 
typical patient up to the point of being 
offered the proposed test and sub-
sequent therapy with the proposed 
drug, as compared to the currently 
existing clinical pathway(s) where 
the proposed test is not offered and 
the proposed drug is not available? 
In these clinical pathways, outline all 
alternative tests/test strategies 
(whether in series or occurring 
concurrently) and all alternative 
treatments (including non-drug 
treatments) for the patient indication 
both with and without knowledge of 
the patient’s biomarker status.  
If it is important for patients with a rapidly progressive disease to ensure 
that a timely test result is available to determine drug eligibility, indicate 
whether the test is therefore likely to be performed earlier in disease 
progression in a broader population than might otherwise be considered  
as potentially eligible for the drug. Identify tests and treatments that are 
commonly used and likely to be supplemented or replaced by the pair of  
co-dependent technologies (see Information Requests 13 and 14). 
13) (T) Can the proposed test be used 
with other treatments and/or for 
other purposes? (Refer to the clinical 
pathways provided in response to 
Information Request 12.) 
If other treatments or purposes are relevant, this would move to a more 
complex scenario. 
14) (T) Is the test an additional test 
to other(s) currently defining the 
condition? Or a replacement test? 
Or both (i.e. depending on the test 
result, replace some tests or be 
additional to other tests)? (Refer to 
the clinical pathways provided in 
response to Information Request 12.)  
Most commonly, the test would be an additional test; although occasionally 
if the biomarker is a strong predictor, then it could replace another test in 
the workup. 
15) (T) How is it suggested that the 
test will be offered?  
Specify the national registration status of the test. Assess access and quality 
assurance issues. Identify how many laboratories offering the test have national 
accreditation for that test. (Note that a way of determining this is not yet 
available.) Indicate whether the test accessibility is likely to be widespread or 
only available in a few selected laboratories across the country. Explain how 
the test would be undertaken in practice and what impact it would have on 
patient and health professionals. Discuss alternative ways to access the test. 
16) (T) Have the following been 
identified: i) the biospecimen 
required to perform the test? ii) 
whether this specimen needs to be 
collected specifically for the purposes 
of performing the test or has already 
been collected for another purpose?  
i) For example: blood, tumour material (formalin-fixed paraffin embedded 
(FFPE) or fresh), bone marrow, cytology specimen, mouth swab. ii) For 
example: tumour already removed can be tested if archival FFPE is available 
and the test can identify the biomarker from this tissue. If a new specimen 
needs to be collected, specify the costs, risks and feasibility of collecting the 
sample. In some instances, such as a blood sample, the costs and risks would 
be trivial. In other instances, such as when a new biopsy is required, there 
may be significant costs as well as safety risks for the patient. 
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17) (If relevant) (T) What is the 
potential need for subsequent testing 
to identify new somatic mutations 
which may guide dosage or cessation 
of therapy with the co-dependent 
drug?  
This will impact on the clinical need for the proposed test as well as its 
potential use to guide drug dosage titration and treatment continuation.  
If subsequent testing is needed, this would move to a more complex 
scenario. 
18) (T) Are the test results expected 
to be consistent over time, including 
over the course of the disease?  
Where test results may change over time, provide sufficient detail to clarify the 
relationship and timeframes between test results and the appropriateness of 
treatment. For example; Kirsten rat sarcoma viral oncogene homolog (K-RAS) 
testing of the primary colorectal cancer tumour is usually representative of 
the findings in metastases. However epidermal growth factor receptor (EGFR) 
results change with exposure to radiotherapy etc. and so the results of testing 
the primary tumour may not be representative of what is happening in  
non‐small cell lung cancer metastases. 
19) (O) Can the proposed drug be 
used with other specific tests for  
that biomarker, other than the test 
proposed? What methodologies are 
available to test for the marker?  
If other tests are publicly funded, this would move to a more complex 
scenario. 
(Source: [9] with minor adaptations) 
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8.2 Qualification: assessing the impact of a biomarker test 
on patient health outcomes 
Table 8.2-1: Checklist: Clinical benefit of the pair of co‐dependent technologies in terms of patient health outcomes  
20) (O) Is there direct evidence of prognostic 
impact associated with different biomarker 
status?  
This is used to discriminate prognostic impact as an alternative  
(or in addition) to treatment effect modification. It requires a 
comparison of outcomes in patients receiving usual care conditioned 
on the presence or absence of biomarker positive status. 
When presenting the body of evidence to address clinical benefit, two different options (Option 1 and Option 2) are 
provided so that available information can be used to maximum effect to inform a reimbursement decision.  
OPTION 1. Is there ‘direct evidence’11 of the 
proposed test's impact on patient health 
outcomes? For example, patients randomised 
to the proposed test or to no test and followed 
through to allocation of the proposed drug or 
usual care and the subsequent impact of that 
treatment on their health outcomes. 
Direct evidence is used to determine whether the pair of  
co-dependent technologies are (cost‐) effective and safe.  
If randomised to use of the test, then biomarker status would be 
known and, on that basis, subsequent targeted therapy or usual 
care could be decided for the patient. If randomised to not using 
the test, then the patient would receive treatment that is not 
targeted by the biomarker result. ‘Direct evidence’ does not 
exclude the need for an assessment of translational issues.  
Level 1: Is a trial available that randomised to 
use of the test or not, and then randomised to 
use of the drug or its main drug comparator, and 
then followed participants to measure clinical 
outcomes (whether surrogate outcomes or 
directly patient relevant outcomes)? See  
Figure 5.2-1– double-randomised controlled trial. 
 
Level 2: If not, is a trial available that 
randomised to the use of the test or not, and 
then followed participants to measure clinical 
outcomes (whether surrogate outcomes or 
directly patient relevant outcomes)?  
See Figure 5.2-1–marker strategy design. 
Given that Level 2 direct evidence does not provide information  
on the test(biomarker)-drug relationship i.e. evidence that the 
biomarker is a treatment effect modifier or prognostic factor, 
therefore consider supplementing with Level 3 or 4 direct evidence 
(also see Information Requests 34 and 35). 
Level 3: If not, is a trial available that 
prospectively tested eligible patients, and then 
randomised test positive or negative patients 
to use of the drug or its main comparator, and 
then followed participants to measure clinical 
outcomes (whether surrogate outcomes or 
directly patient relevant outcomes)? See Figure 
5.2-1– marker by treatment interaction design/ 
randomised trial of drug only (with the eligibility 
of all subjects determined by test result). 
Given that Level 3 and 4 direct evidence effectively involve 
uncontrolled study designs (i.e. there is no trial arm provided to 
assess the impact of not testing biomarker status), consider 
providing a supplementary ‘linked evidence’ approach (see Option 
2 below) so that at least a comparison of the proposed test/test 
strategy and existing test/test strategy can be made with respect 
to their relative diagnostic accuracy. 
Level 4: If not, is a trial available that 
randomised eligible patients to use of the drug 
or its main comparator, and then followed 
participants to measure clinical outcomes 
(whether surrogate outcomes or directly patient 
relevant outcomes), and then analysed results 
across subgroups of patients defined by whether 
they are positive for the test (or biomarker) or 
whether they are negative to the test (or 
biomarker)? See Figure 5.2-1 – biomarker-
stratified design / randomised trial of drug only 
(with the test result determined through 
subgroup analysis). 
Level 4 direct evidence may use archival tissue/sampling to 
determine biomarker status. Exercise caution when interpreting 
results from Level 4 studies where biomarker status might change 
over time, including where there is evidence that intervening 
treatment may modify the biomarker. 
Level 5: If not, then move to corresponding 
guidance on ‘linked analyses’  
(see Option 2, below).  
 
                                                             
11 Direct evidence: a trial that compares groups of people receiving either the currently used diagnostic test/test strate-
gy or the proposed diagnostic test/test strategy and measures the differential impact of the diagnostic method on 
patient health outcomes [8]. 
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21) (O) Is the direct evidence presented and 
selected in a comprehensive and unbiased 
manner?  
For example, present a systematic review of direct evidence 
concerning this pair of proposed test and proposed drug for this 
biomarker with pre-specified inclusion/exclusion criteria and a 
PRISMA flowchart indicating how trials were selected and the 
reasons why any potentially relevant trials were excluded. 
22) (O) Is the direct evidence of good quality?  Assess bias, confounding, the impact of chance on results and 
whether the analyses were pre-specified and/or exploratory. Use an 
intervention study design critical appraisal checklist to cover all issues 
likely to affect the internal validity of the presented trial results. 
23) (O) Does the direct evidence provided 
show a clinically important and statistically 
significant impact on patient-relevant health 
outcomes?  
Assess both effectiveness and safety. Describe outcomes in the 
studies (primary and secondary outcomes) and statistical methods 
used. Provide an extended assessment of comparative harms. 
Assess the balance of benefits and harms and interpret findings 
from the body of evidence. 
24) (O) Is the direct evidence provided 
applicable to the requested populations? 
Translation steps (applicability, transformation and extrapolation):  
 address external validity concerns of trials usually conducted in 
a different setting or with a different population (i.e. spectrum 
of disease)  
 address concerns that usually relate to the length of follow-up 
of the direct evidence, to the use of surrogate outcomes and 
most importantly to capture the point estimate and confidence 
limits of the treatment effect taking into account the impacts 
of incorporating the test results. 
 Describe patient characteristics in the trials and indicate whether they 
are relevant to the national situation. Indicate whether the requested 
technologies were provided in a setting similar to the setting of use.  
OPTION 2. Is there ‘linked evidence’ available of 
the test's impact on patient health outcomes? 
In other words, can different types of evidence 
from different sources be linked in a chain of 
argument to estimate this impact?  
For example, this might involve linking evidence of test accuracy 
with evidence that the test result changes patient management, 
and with evidence that the alternative treatments have different 
effectiveness and safety profiles. Further background is provided in 
the 2005 Medical Services Advisory Committee (MSAC) Guidelines 
[8]for the assessment of diagnostic technologies. Note that a full 
linked evidence approach is only meaningful when the evidence for 
the proposed test and the evidence for the proposed drug have 
been generated in similar patient populations and so it is clinically 
sensible to link the two data sets. If the test identifies patients 
earlier or with a different spectrum of disease than the patients in 
whom the drug has been trialled, then it is not clinically sensible to 
link this evidence. In such circumstances direct evidence is needed.  
What is the test effectiveness and safety? 
25) (T) What is the analytical test 
performance?  
Analytical test performance assesses how accurately and how 
consistently the test identifies biomarker status, e.g. the coefficient 
of variation and other appropriate statistics. Present any differences 
across laboratories in how they characterise test results (e.g. a kappa 
statistic or other concordance statistic). Identify whether there is 
an external quality assurance program by which laboratories can 
benchmark their assays. 
26) (T) Is there a clinical reference standard  
or a 'gold' standard against which test 
performance can be measured? 
Indicate whether this clinical reference standard is also the relevant 
diagnostic comparator, i.e. the current test/test strategy being 
used in the absence of the proposed test. 
Note: there are statistical solutions for situations when a reference 
standard is imperfect or not available or impractical (construct a 
reference standard, predictive accuracy, adjustment of accuracy 
estimates for workup bias), which are detailed elsewhere [74]. 
If a reference standard is available: test 
performance is determined using diagnostic 
accuracy measures. 
Test performance measures include: sensitivity, specificity, likelihood 
ratios, positive and negative predictive values, area under curve (AUC). 
Designate a reference standard and compare the proposed test to the 
designated reference standard by cross classifying the test results 
of patients who are representative of the intended use population. 
Include confidence intervals and significance levels to quantify the 
statistical uncertainty in these estimates due to the subject/sample 
selection process. This type of uncertainty decreases as the number 
of participants in the study increases. Assess whether there is a test 
performance level below which the test should not be used (for 
example, either false positives are too great or false negatives are 
too great) so that other better performing tests are needed.  
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27) (T) Is the evidence of diagnostic or 
predictive accuracy presented and selected  
in a comprehensive and unbiased manner?  
For example, present a systematic review of diagnostic accuracy 
studies for this test with inclusion/exclusion criteria delineated and 
a PRISMA flowchart indicating how trials were selected and 
reasons why any potentially relevant trials were excluded. 
28) (T) Is the evidence of diagnostic or 
predictive accuracy of good quality?  
See Table 6.1-1 QUADAS~ checklist. 
29) (T) Are there any safety considerations that 
will impact on the entire process of testing?  
 
30) (T) Is the evidence of test accuracy and 
safety applicable to the requested populations?  
Assess whether test accuracy was determined in the correct 
population. See Table 6.2-1 QUADAS~ checklist. 
31) (If relevant for a comparison of tests) (T) 
Which test has the best test performance (in 
terms of accuracy and/or clinical benefit)?  
Assess trade-offs in false positives, false negatives, and in positive 
predictive value and negative predictive value. If other tests are 
publicly funded, this would move to a more complex scenario. 
32) (If relevant for a comparison of tests) (T) 
Which test is most accessible/ available/ used?  
Assess access and quality assurance issues. If other tests are 
publicly funded, this would move to a more complex scenario. 
33) (O) Will knowledge of the test result cause 
a change in the management of the patient by 
the treating clinician? Are there instances where 
management would not change, despite the 
test indicating the biomarker is present?  
There may be 'leakage' issues identified through an assessment of 
the 'change in management' part of a linkage. Often a test is done 
to rule out a drug (e.g. to avoid potential drug-related adverse 
events or the development of drug resistance), but the drug is given 
anyway, or, alternatively, the test is used to select a specific drug, 
but the drug is not provided. As companion tests in a co‐dependent 
pairing will often be used to guide drug therapy decisions, this 
would need to be explicitly addressed. Once listed, these issues 
could be informed by data that compare the numbers of test 
'positive' results and prescriptions filled for the drug. 
What is the test-drug effectiveness and safety? 
34) (O & D) Is there evidence available of 
treatment effect modification or significant 
interaction between biomarker status and 
treatment outcomes? For example, is there 
evidence of substantial variation in a measure 
of relative treatment effect between the 
proposed drug and usual care trial arms after 
stratifying for biomarker status?  
Treatment effect modification in this setting identifies a relationship 
between the biomarker and the drug, which is likely to be unique 
or limited to companion tests assessing a particular biomarker and 
drugs with a particular mechanism of action. This means that both 
technologies are required to produce a clinical benefit and the 
reimbursement decision may need to encompass both technologies. 
35) (O & D) Is there evidence available of 
better targeting to patients likely to respond 
most by using the prognostic impact of the 
biomarker to determine the baseline risk of 
disease progression? For example, is there 
evidence of minimal variation in a measure of 
relative treatment effect between the proposed 
drug and usual care trial arms, but biomarker 
status helps identify patients at greatest risk of 
an event which helps maximise the absolute 
treatment effect?  
If a drug’s result is due to better targeting to those patients that are 
likely to respond most, this identifies a relationship between the 
biomarker and a potentially broader range of existing and future 
treatment options (potentially including non-drug treatment 
options) than is likely to apply for treatment effect modification.  
It is possible for both treatment effect modification and prognostic 
impact to co‐exist. In this case, in order to assess the unique 
contribution of the drug therapy, an assessment of its effect must 
be made relative to usual care and adjusted for the background 
prognostic impact that is operating in both the drug and usual care 
arms and which is also flagged by that particular biomarker.  
By contrast, if the drug's apparent improvement in result is simply 
due to the fact that a certain patient subgroup (flagged by a specific 
biomarker) will always do better, then the level of co‐dependency 
between the technologies is low. This may allow reimbursement of 
either test or drug or both technologies. 
36) (O & D) Is the drug effectiveness evidence, 
as conditioned by the test or biomarker result, 
obtained in a comprehensive and an unbiased 
manner?  
For example, present a systematic review of randomised trials of 
the proposed drug targeting this biomarker with inclusion/exclusion 
criteria delineated and a PRISMA flowchart indicating how trials 
were selected and reasons why any potentially relevant trials were 
excluded. 
37) (O & D) Is this drug effectiveness evidence, 
as conditioned by the test or biomarker result, 
of good quality?  
Assess bias, confounding, the impact of chance on results and 
whether the analyses were pre-specified and/or exploratory. Use 
an intervention study design critical appraisal checklist to cover all 
issues likely to affect the internal validity of the presented trial 
results. Confounding may occur as a consequence of imbalance in 
biomarker status in the drug and usual care trial arms in the case 
where biomarker status is also a prognostic factor. 
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38) (O & D) Does this drug effectiveness 
evidence, as conditioned by the test or biomarker 
result, show a clinically important and statistically 
significant impact on patient-relevant health 
outcomes (both safety and effectiveness)?  
Relate this to factors intrinsic to the proposed drug:  
i) treatment effect modification when prognostic impact is not 
present in the drug/biomarker relationship, and/or  
ii) absolute treatment effect when prognostic impact is present in 
the drug/biomarker relationship (see Information Request 35). 
And to the factor intrinsic to the proposed test:  
iii) identification of true biomarker status given test result status 
(i.e. positive predictive value and negative predictive value) or 
evidence that there is complete agreement on an individual 
patient level between test outcomes across the proposed test 
and the test used to identify patients in the evidence provided. 
39) (O) Is the evidence supporting the pairing 
of the co-dependent technologies applicable to 
the intended populations?  
 
(Source: [9] with minor adaptations) 
